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Abstract 
RNAi has great potential in future therapeutics as it has the ability to regulating many 
disease-related genes. However, many barriers prevent practical applications. To overcome 
the barriers, the specific targeting, efficient delivery system, the validated gene and the potent 
siRNA sequence are all vital important. The studies throughout this thesis have been focued 
on examining the validation of three RNAi therapies for two different disease models: 
allergic contact dermatitis and melanoma. For allergic contact dermatitis, I developed and 
tested a novel topical delivery system for siRNAs targeting TNFα (siTNFα) and MyD88 
siRNA (siMyD88). While siRNAs applied without the transdermal enhancer are ineffective, 
treatment with combined siMyD88 and siTNFα significantly attenuated contact 
hypersensitivity (CHS) symptoms in mice, and did so better than treatment with siMyD88 or 
siTNFα as single agents. This is the first demonstration of topical gene silencing of TNFα 
and MyD88 to treat allergic reactions, highlighting a potential clinical use of RNAi therapy 
for skin and allergic diseases. For melanoma, I examined two RNAi therapies using 
liposomes attached to mannose and folate ligand, respectively. We developed a novel DC 
(dendritic cell)-targeted siRNA delivery system using mannosed liposomes (Man-lipo) with 
encapsulated IDO siRNA (Man-lipo-siIDO), which preferentially knocks down IDO in DCs. 
Mice treated with Man-lipo-siIDO had a delayed time of onset of implanted murine 
melanomas, increased survival time, reduced tumour size, and increased reactivity of T cells 
from spleen and lymph nodes against melanoma antigens. This study supports the concept 
that Man-lipo-siIDO has potential for development as an immune-targeting therapeutic 
anticancer agent. We constructed a liposomal folate receptor-targeting siRNA delivery 
system. Compared to controls (non-treatment mice, mice treated with Folate-lipo-siScramble, 
or with non-folate-lipo-siBRAF), mice treated with Folate-lipo-siBRAF had reduced tumour 
volume, lower tumour weight, and reduced expression of PCNA and vascular networks in 
tumour tissue. This study highlights the potential of Folate-lipo-siBRAF for development as 
an anticancer therapeutic agent. In conclusion, the therapies for allergic dermatitis that use 
topical delivery of siTNFα and siMyD88, for melanoma using the Man-lipo-siIDO or the 
Folate-lipo-siBRAF, have the potential to be effective RNAi therapies to treat allergic 
dermatitis and melanoma. 
Keywords 
RNAi therapy, siRNA delivery, Allergic contact dermatitis; siRNA; MyD88; TNF-α, 
melanoma, IDO, BRAF, mannose, folate, tumour siRNA delivery, topical siRNA delivery.  
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Chapter 1  
1 Introduction 
1.1 RNAi and siRNA 
1.1.1 History of RNAi 
Before 1980, RNA was viewed as an inert nucleic acid intermediate for protein 
production. This view has changed in the 1980s when Sidney Altman and Thomas Cech 
were recognized with a Nobel Prize for their discoveries describing catalytic RNAs [1, 
2] . This development inspired many researchers to shift their attention towards these 
nucleic acids.  
In the late 1980s and early 1990s, many studies demonstrated that expression of sections 
of a viral genome in plants protected them from infection by the subsequent virus and 
related viruses [3]. It was also found that transgenes led to the silencing of endogenous 
genes in a homology-dependent manner and the transgene-mediated gene silencing or 
viral protection showed sequence specificity [4, 5]. However, in transgene technology, 
researchers observed two unexpected complications. First, most plants with an antisense 
transgene did not exhibit suppression of the corresponding endogenous gene [6]. Second, 
some of the control lines with the sense construct exhibited coordinate suppression (co-
suppression) of the transgene and the homologous endogenous gene [4, 7, 8]. Although 
both the antisense and co-suppression mechanism were known to function at the post-
transcriptional level, the mechanisms were actually not well understood and so were not 
viewed as connected [9].  
In 1998, an inspired analysis involving the nematode Caenorhabditis elegans revealed 
that injected double-stranded (ds) RNA containing both sense and antisense RNA 
preparations could specifically target endogenous mRNA before translation and induce 
genetic interference. This phenomenon was named RNA interference (RNAi) by Fire and 
colleagues [10-12]. Subsequently, (during 1998 and 2000) it was established in plants 
that if dsRNA was produced, suppression of endogenous gene expression was more 
efficient than in response to sense or antisense transgenes applied alone. Inverted repeat 
2 
 
transgenes were particularly efficient, but simultaneous expression of sense and antisense 
RNA was also effective [13, 14].  
In 1999, the presumably antisense RNA that guided the degradation of the co-suppressed 
RNA was discovered when the size was redirected from >100 nucleotides to up	to	25 
nucleotides [15]. This second important discovery followed from the search for the 
specific determinant of co-suppression in plants. This link between the short RNAs and 
RNAi was subsequently confirmed in Drosophila melanogaster. The same work also 
confirmed the prediction that the short RNAs guide a ribonuclease complex called RNA 
Induced Silencing Complex (RISC) to its target RNA in RNAi [16].  
The discovery that short RNAs play a key role in RNAi-mediated suppression of gene 
expressions precipitated an avalanche of discoveries that are relevant to the application of 
RNAi and co-suppression, as well as understanding of the natural roles of these processes. 
For example, short RNAs have been characterized in detail and are now known to exist in 
a double-stranded form, with two-nucleotide overhangs at each 3′ end, and are known as 
small interference RNA (siRNAs) [17].  
During and around 2002, several different proteins were identified as associates with 
siRNAs in ribonucleo-proteins [18, 19]. The mechanism for how dsRNA is processed 
into siRNAs has also been established. The processing enzyme is known as Dicer, a 
member of the RNase III family with dsRNA binding regions and a conserved PIWI–
Argonaute–Zwille (PAZ) domain shared with members of the piwi, argonaute and zwille 
enzyme family[20], from which it takes its name. ATP is required at several stages in the 
processing of dsRNA and assembly of RISC [21]. In some instances an RNA-dependent 
RNA polymerase is also involved in converting a single-stranded RNA into a double-
stranded siRNA precursor [22-24]. 
The discovery of RNA-mediated gene silencing, changed our view of gene regulation and 
led to the development of new genetic tools and methods for selective gene silencing, and 
have opened a window for developmemt of novel therapeutics against various 
diseases[25].  
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1.1.2 Mechanism of RNAi action 
RNAi is a naturally evolved mechanism in nematodes, insects and plants, as a result of a 
developed intrinsic defense against RNA virus and transposons [26]. This characteristic 
makes it ideal as the basis for a physiologic approach for both in vitro and in vivo gene 
silencing [20, 27]. This mechanism has been described in several eukaryotic organisms 
such as Neurospora [28], Drosophila spp [29-31], and mammals [32, 33], including 
human cell lines and primary cells [34].  
RNAi is induced by endogenous and exogenous small RNAs that include siRNAs and 
microRNAs (miRNAs) [32, 35] (Fig 1-1). The process is initiated through cleavage of 
dsRNA by a two-subunit RNAse III-family enzyme called Dicer located in the cytoplasm. 
This results in smaller, 21-23 nucleotide-long dsRNA fragments termed siRNA 
molecules. Each of these siRNA molecules consists of both a sense and an antisense 
strand to the homologous RNA target messenger RNA (mRNA) sequence. These siRNA 
molecules serve as a trigger for the RISC cellular machinery, composed of associated 
proteins and RNA nucleases, which selectively degrade the target complementary mRNA 
[20, 36, 37].The endonuclease Argonaute 2 (AGO2) is responsible for the cleavage 
mechanism of RISC, and AGO2 is the only member of the Argonaute subfamily of 
proteins with observed catalytic activity in mammalian cells [38]. AGO2 is the critical 
enzymatic component of RISC: it carries two characteristic domains, named PAZ and 
PIWI. RISC activation is thought to initially involve AGO2-mediated cleavage of the 
sense or passenger strand of the double-stranded siRNA [39, 40], yielding the single-
stranded antisense strand that serves to guide RISC to complementary sequences in target 
mRNAs. This guide strand is bound within the catalytic, RNase H-like PIWI domain of 
AGO2 at the 5′ end [41] and a PAZ domain that recognizes the siRNA 3′ end [25, 42]. 
The cleavage of targeted mRNA takes place between bases 10 and 11 relative to the 5′ 
end of the siRNA guide strand [43], resulting in subsequent degradation of the cleaved 
endogenous mRNA [44]. On activation by the siRNA guide strand, RISC can undergo 
multiple rounds of mRNA cleavage to mediate a robust post-transcriptional gene 
silencing (PTGS) response against the target gene [45]. 
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Figure 1-1 RNAi Pathway. Adapted from QIAGEN: 
http://www.qiagen.com/products/genes%20and%20pathways/Pathway%20Details.a
spx?pwid=398 
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PTGS by mRNA cleavage has been exploited as the method of choice for potential 
therapeutic applications of RNAi because of the potency of this catalytic gene-silencing 
pathway [46]. In addition to cleavage of perfectly complementary mRNAs, translational 
repression and transcript degradation (for imperfectly complementary targets), RNAi 
pathways can also direct transcriptional gene silencing (TGS) in the nucleus [47, 48].  
 
1.1.2.1 Maximizing Gene Silencing by RNAi 
Maximizing the activity of the effector sequence could be vitally important as it 
influences conditions for cellular introduction and/or expression and subsequence 
processing [49, 50].  For example, it is been shown that the stable 5’end of antisense 
RNA are preferentially incorporated into RISC [49, 51]. Thus, it implies that there are 
biases in designing RNAi effectors as better guide strands. There are additional biases in 
other positions; for example, high thermodynamic stability is preferred between 
nucleotides 5-10 of the guide strand. Furthermore, by comparing multiple sets of active 
and inactive siRNA sequences, much experience has been accumulated and is being 
applied to the design of optimally active siRNA sequences. Many design tools have been 
developed, and have been applied in commercially-available RNAi molecules. To 
maximize RNAi activity, it is also important to record and organize the increasing 
number of validated sequences developed by the scientific community and commercial 
sources. RNAi effectors are designed to correspond to reported active endogenous RNA 
sequences. Targeted sequences that are similar to unreported sequences in the genome 
(including, for example, single nucleotide polymorphisms or SNPs), might lead to RNAi 
effectors being unable to efficiently induce RNAi [52]. However, the influence might be 
less than predicted, since RISC is able to tolerate some mismatches, especially those far 
from the cleavage site [53, 54]. Despite aberrations in target RNA that could influence 
RNAi, they also have the potential to be used to more specifically target mutated 
transcripts that relate to disease. This approach has been applied in several contexts, such 
as targeting of cancer-specific mutations, targeting of a single-base mutation associated 
with the dominant genetic disorder spinocerebellar ataxia, and the silencing of mutant β 
globin as an approach to treat sickle cell anemia [54-56]. In addition to potential 
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sequence discrepancies, transcript variants of genes targeted for downregulation using 
RNAi must also be considered when designing RNAi effectors. With increased 
understanding of RNAi, use of more than one effector against target RNA is 
recommended when testing the specificity and activity of RNAi-mediated reduction of 
each target [57].  
 
1.1.2.2 Off-target effects associated with RNAi 
To achieve the best silencing efficiency for RNAi effectors, minimization of off-target 
effects is critical. Off-target effects can result from several events, including both 
sequence-independent and sequence-dependent processes.  
Sequence-independent effects (so-called nonspecific effects) are related to transfection 
conditions, inhibition of endogenous miRNA activity, and stimulation of pathways 
associated with the immune response. Examples of sequence-independent nonspecific 
effects include RNAi machinery saturation [58-60] and immune response against RNAi 
effector [61-65]. The studies revealing these effects strongly suggest that the use of the 
lowest effective RNAi effectors, and incorporation of negative control RNAi effectors as 
comparitors into design of experiments, is essential when planning studies that use RNAi 
to explore the function of RNAs.    
Sequence dependent effects are associated mainly with associations between RNAi 
effector molecules and non-targeted RNAs that are partially complementary to those 
RNAi effector molecules: in this case, those non-targeted nucleic acids are silenced by 
miRNA-like interactions [65]. Sequence-dependent effects also include receptor-
mediated immune stimulation where certain short nucleotide sequences are recognized by 
receptors and are activated by interaction with them [65]. 
Furthermore, where RNAi is applied in vivo, off-target delivery could induce specific or 
non-specific silencing effects in non-targeted organs, tissues or cells. This possibility is 
described below (section 1.4, page15).  
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1.2 Application of RNAi 
1.2.1 In vitro RNAi application 
When RNAi is used to target gene expression, gene-specific reagents are introduced into 
cells to trigger ‘knockdown’ or reduction of gene function via sequence-specific 
degradation and translational interference of mRNA transcripts. This method has truly 
revolutionized the field of functional genomics because, unlike other traditional genetic 
screening methods, RNAi provides a powerful reverse genetic approach, especially for 
organisms with complex genomes a large number of genes (including mammals). 
Therefore, RNAi can be used as a powerful tool for genomic studies [66-72]. RNAi 
screening provides a powerful reverse-genetic approach for large-scale functional 
analysis in cells grown and studied in culture. Cell-based RNAi screening builds upon 
established instrumentation and assays, and other methods previously developed for 
chemical screening that provide a relatively rapid and accessible platform for genome-
scale functional studies [66, 68, 69, 71]. A large number of RNAi screens have been 
performed in cultured insect (Drosophila) and mammalian cells [66].   
Most RNAi-based experiments are designed to achieve sequence-dependent cleavage and 
reduction of protein-encoding mRNAs. Although most studies focus on the RNAi 
analysis of these targets, any RNA species can be targeted (for example, noncoding RNA 
transcripts or viral RNAs). Only a small number of mammalian cell types can tolerate 
RNAi induced by large, exogenous dsRNAs (e.g., embryonic stem cells). Thus, in 
mammalian systems, it is necessary to select from a variety of RNAi effector molecules 
to achieve specific target reduction without unacceptable toxicity. Effector molecules 
include siRNA duplexes formed by annealing of two independent RNA strands, or 
single-stranded RNA molecules that contain a dsRNA domain, termed short hairpin 
RNAs (shRNAs) may be employed. ShRNAs are synthesized from siRNA duplexes that 
formed through the annealing of two independent RNA strands, or single-stranded RNA 
molecules that contain a dsRNA domain. Both are designed to have full complementarity 
with target transcript mRNA without regions of non-complementarity, resulting in target 
cleavage and degradation [66].  
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SiRNAs used to target RNAs in cultured cells can be generated by annealing single-
stranded synthetic oligonucleotides. Most synthetic siRNAs consist of 19 perfectly 
matched complementary ribonucleotides with unmatched, single-stranded 3’dinucleotide 
overhangs. For ease of synthesis, the synthetic oligonucleotides annealed to generate 
siRNAs are often deoxyribonucleotides. SiRNAs can also be generated by a number of 
other methods including in vitro transcription, plasmid-based tandem or convergent 
expression cassettes, polymerase chain reaction (PCR) [57], but siRNAs generated by 
annealing synthetic oligodeoxynucleotids are most common. Transfected siRNAs can 
yield a substantial decrease in the steady-state levels of target mRNAs for approximately	
24 - 120 h [57]. 
ShRNAs are designed to mimic miRNA precursors, which are then processed by the 
endogenous RNAi machinery and loaded into RISC complexes. A number of different 
shRNA expression systems, where shRNA expression vectors are transiently or stably 
incorporated into target cells, have been described. Variations in the structure of those 
vectors include differences in promoter-terminator combinations, linker sequences, 
flanking sequences, duplex length, and regulatory elements that can be used for spatial 
and/or temporal specific expression. Additionally, selection markers, used to generate 
stable cell lines, and unique sequence elements, used to identify active shRNAs among 
larger populations, have been employed. As opposed to siRNAs, the stable expression of 
shRNAs allows for a non-transient reduction of targeted mRNAs. Thus, the choice of 
RNAi effector (siRNA or shRNA) depends on the situation under investigation [57].  
In this study, we focus on the transient siRNA RNAi effector over shRNA in treating 
allergic contact dermatitis and melanoma for several reasons: First, allergic contact 
dermatitis, a disease induced by the immune systems response to repeated contact with 
antigens, does not warrant the long-term silencing of anti-immune-response genes, such 
as Tumour necrosis factor alpha (TNF-α) and Myeloid differentiation primary response 
gene 88 (MyD88). Consequently, prolonged downregulation of these genes once the 
antigen has been removed could increase the risk of future pathogen invasion. Second, in 
targeting the host endogenous immune-tolerance gene indoleamine 2, 3-dioxygenase 
(IDO) for silencing in melanoma using RNAi, it is understood that this is a normal gene 
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that is abnormally expressed in host during the course of the disease. Because IDO is not 
normally expressed in adult tissues, it is expected that the normal immune balance will 
not be influenced by the silencing effect in the therapy. Third, in targeting the B-RAF in 
melanoma, we used the RNAi effector (siRNA) that was fully complementary with the 
normal B-RAF mRNA and transiently transfected rather than stably incorporated into 
target cells. Thus, rather than long-term silencing, transient silencing of the gene in 
tumour tissue was preferred. Here, the transient silencing effects of siRNA offer the 
benefit of repeated application of the effectors without long-term effect. Stable silencing, 
on the other hand, is mediated by shRNAs that are transported to the cytoplasm via the 
miRNA export pathway and processed into siRNAs by Dicer. Direct use of synthetic 
siRNA effectors is simpler, does not involve intermediate processer by Dicer, and usually 
results in potent gene silencing [73]. Fifth, the method of antisense delivery needs to be 
considered. ShRNAs are most efficiently delivered by virus while siRNAs can be 
delivered through many of non-viral vectors, such as cationic lipids or polymers [74]. In 
our study, siRNAs, but not shRNAs, could be efficiently delivered into cells by a topical 
delivery system. We also used a lipid based system to achieve tissue or cell specific 
delivery, which performing well in delivering reagents to targeted tissues and cells in 
circulation. Moreover, in our lipid based delivery system, we had difficulty in achieving a 
shRNA-lipid complex size less than 200 nm in diameter, while 100nm has been described 
as the optimum for nano-particles to achieve tissue penetration and cell entry.  
Regardless of the RNAi effector used, it is important to include negative control effector 
molecules in any RNAi-based experiment. The siRNA controls which are usually 
commercially available incorporate sequences with minimal complementarity to any 
endogenous transcript.  
 
1.2.2 In vivo RNAi applications 
RNAi has great potential to be used in many genetic or acquired diseases. It can be used 
to reduce the levels of toxic gain-of-function proteins, trigger cytotoxicity within tumours, 
and block viral replication [75, 76]. RNAi can be used to regulate the expression of 
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proteins that are not easily accessed by traditional pharmacological approaches, such as 
molecules lacking ligand-binding domains or proteins that share high degree of structural 
homology. Thus, RNAi based therapeutic approaches are especially appealing to achieve 
a high degree of specificity and to target molecules that are considered to be 
“undruggable”. In vivo RNAi-mediated knockdown in mouse liver has been reported as a 
consequence of high-pressure tail vein injection of both siRNAs and shRNAs [75, 76]. 
Subsequent in vivo studies have focused on the improved delivery and efficacy of RNAi 
effectors. These efforts have used the experience gained through two decades of 
developing ribozyme and antisense-based therapeutics and the gene therapy field as a 
whole [57, 66].  
Several proof-of-principle studies have shown the delivery of fluorophor-labeled siRNA 
molecules into various organs [77-79]. Beyond that, the specific in vivo knockdown of 
artificially introduced reporter genes like green fluorescent protein (GFP) or luciferase, or 
various endogenous target genes, has been described. Due to the body’s natural tendency 
to process injected delivery vehicles in the liver, it has become the common target for 
antisense therapy, but gene targeting in other organs or in tumour xenografts has been 
reported as well. Taken together, these studies provide valuable insights into the delivery 
and efficacy of siRNAs for the induction of RNAi [57, 80, 81]. RNAi-based methods are 
now a common tool for gene perturbation in mammalian tissue culture cells (mouse, rat, 
monkey, and human). Beyond cell culture screens, RNAi is being used in a number of in 
vivo studies where the RNAi reagents are delivered topically and directed to specific 
tissues or organs, such as the retina, brain, or muscles; used ex vivo (for example in 
hematopoietic cells); or delivered as transgenes [67, 82].s 
 
1.3 RNAi therapies 
RNAi has great potential in future therapeutics as it has the potential to regulate disease-
related genes. In essence, all any human disease caused by inappropriately increased 
activity of one or more genes could, in theory be regulated by RNAi-based therapies [73]. 
The numbers of RNAi-based preclinical and clinical trials have grown over the past 
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several years and have included studies in retinal degeneration, dominant-negative 
inherited brain and skin diseases, viral infections, respiratory disorders, cancer and 
metabolic diseases [83]. To date, RNAi therapies in clinical trials have targeted 
approximately 14 different diseases [83]. Numerous siRNA therapies are at preclinical 
stage. The delivery methods for siRNA drugs are continually improved to maximize the 
specificity of siRNA delivery while minimizing toxicity and degradation effects that 
compromise drug efficacy [74]. Strategies exist that use synthetic materials or natural 
carriers (viruses and bacteria), and the preferred method typically depends on the 
application, the required duration of the therapeutic, and the targeted tissue.  
Three clinical trials have used ex vivo delivery of the siRNA/shRNA therapeutics, in 
which cells were collected from patients, treated with siRNAs/shRNAs and re-
implanted/re-infused back into the patient [81]. This procedure is known as autologous 
cell therapy. One of the three clinical trials involves use of an anti-tumour bifunctional 
siRNA (bi-siRNA) for treatment of metastatic melanoma. A phase I clinical trial at Duke 
University (Durham, North Carolina, USA) is focusing on an siRNA drug to treat 
metastatic melanoma, a form of cancer that originates in melanocytes. Patients in this 
study are treated with autologous DCs (dendritic cells) transfected with siRNA in 
combination with mRNAs that encode for various tumour antigens. The purpose of this 
therapy is to install an anti-melanoma immune response by alteration of proteasome-
mediated processing in combination with increased immune recognition of melanoma-
associated antigens [84, 85]. The siRNA-induced knockdown of the proteasome is 
thought to enhance the presentation of melanoma antigen by the DCs with the aim of 
provoking a strong immune response against the melanoma cells in these patients. Ideally, 
cancer cells will be killed through the actions of the patient’s own immune system. Part 
of this thesis (on pages 104 to 133) describes an APC-targeting siRNA therapy for 
treatment of melanoma. In this approach, I used the strategy of silencing IDO expression 
in antigen presenting cells (APCs) in order to reinstall the capacity of endogenous 
immune cells to recognize tumour antigens and activate anti-tumour immune response 
against cancer cells.  
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To date, there are nine siRNA therapies at various stages of clinical testing, all involving 
intravenous injection as the route of administration. Among these are five that use a 
cationic liposome delivery technology, four that use the stable nucleic acid lipid particle 
(SNALP) carrier developed by Tekmira, and one that uses an siRNA-lipoplex known as 
AtuPLEXTM [86-90]. A Phase I clinical test that is currently being conducted by Silence 
Therapeutics (London, UK) that employs an siRNA lipoplex that targets proteins kinase 
N3 (PKN3) in advanced solid cancers [91, 92]. In two studies described in this thesis (on 
pages 104 to 133 and 140 to 170), we also employ cationic liposomes as the delivery 
system and use siRNA lipoplexes as a potential therapy for treatment of melanoma. In 
our studies, we tested the use of targeting ligands to guide siRNA lipoplexes to specific 
cell types and achieve specific gene downregulation preferentially in target cells that 
express molecules on their surfaces capable of binding those ligands.  
Systemic delivery methods that often require injection of the siRNA into the bloodstream 
are being tested for siRNA delivery to the kidney, liver, and some solid tumours [90]. 
Similarly, RNAi drug candidates can be injected directly into the desired tissue or tumour 
to release the drug with the degradation of a biodegradable carrier. Tissues such as the 
eye, lung and skin are suitable for topical delivery siRNA [93]. 
 
1.3.1 The potential of RNAi therapy for cancer 
Cancer is a disease characterized by self-sufficiency in growth signalling, insensitivity to 
growth-inhibitory signals, evasion of programmed cell death (apoptosis), limitless 
replicative potential, sustained angiogenesis and tissue invasion [94-98]. Malignancy is a 
result of long-term accumulation of genetic and epigenetic alterations. While various 
cancers and/or different patients commonly share some of those alterations, heterogeneity 
is usually unique in different tumours and in different patients. As a result, tumour 
molecular profiles differ from patient to patient and personalized therapy is needed. 
RNAi has the advantages of specificity, adaptability and breadth of targeting capability, 
thus giving it great potential to serve as a method for personalized gene therapy for 
cancer. Antisense therapy in particular has advantages in knocking down RNA targets 
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that are up-regulated during, and/or are causally related to, cancer progression. In 
addition, upregulated proteins that mediate malignant characteristics and are, for a variety 
of reasons, difficult to target with small molecules or antibodies (e.g., poor affinity for 
target, cross-reactivity with other essential molecules in normal cells leading to 
unacceptable toxicity) may be good choices for suppression using RNAi targeting the 
mRNAs that encode them.  
 
1.3.2 Challenges in tumour siRNA delivery 
There are many challenges to applying siRNA in cancer therapy, including the major 
issue of selective delivery of intact siRNA to target cells and cellular compartments. The 
common barriers for siRNA delivery to both non-solid cancers (e.g., leukemia) and solid 
tumours are degradation in the blood stream and extracellular fluids (including both the 
stability of the delivery system and the siRNA itself), surface opsonization and 
subsequent entrapment by the mononuclear phagocytic system and reticuloendothelial 
system, and rapid renal clearance [99, 100]. For solid tumours, which make up  85% of 
human cancers, the delivery of siRNA from injection site to tumour involves transport by 
the circulation system to tumours, extravasation from tumour vasculature, and transport 
in tumour interstitium. In this process, diffusion and convection is more important than 
transcytosis [101]. There are barriers in each of the processes. 
Tumours have vasculature that is poorly organized, tortuous, defective and displays 
location-dependent heterogeneity [102]. Compared to normal tissue, tumours have lower 
blood flow, higher flow resistance and, as a result, lower exposure to siRNA injected 
intravenously. On the other hand, tumour blood vessels have discontinuous endothelium 
which makes them leaky and permeable to larger size molecules (100–780 nm). This 
property facilitates diffusion of larger siRNA-containing nanoparticles (e.g., 100 nm 
diameter or more) from blood vessels into the interstitial space to allow passive tumour 
targeting [102].  
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In solid tumours, the lymphatic system is impaired, preventing particulates and interstitial 
fluid from rejoining circulating blood. This enhances retention of macromolecules and 
siRNA-containing nanoparticles in tumour interstitium which, combined with the effect 
of leaky blood vessels in tumours, results in enhanced permeability and retention (EPR) 
of administered therapeutic nucleic acids in tumours[103]. The absence of lymphatic 
drainage also increases the interstitial fluid pressure (IFP) which, in turn, reduces the 
hydraulic conductivity and fluid flow, and results in reduced of convective extravasation 
and interstitial transport.  
Interstitial transportation of siRNA-containing nanoparticles into tumour cells occurs 
mainly through convection, which depends on hydraulic conductivity and pressure 
gradient. The structure of the extracellular matrix (ECM) or stroma creates barriers for 
siRNA transport. Proteins found in the ECM such as collagens, glycosaminoglycans, 
preoteoglycans, fibrous proteins and glycoproteins, pose barriers to siRNA-containing 
nanoparticle delivery by presenting physical obstacles or by binding to the complex [102]. 
 
1.4 Introduction to siRNA delivery 
Over the past two decades, altering or manipulating gene expression has shown great 
potential in a wide variety of diseases. Since the idea of gene delivery illustrates 
treatment of disorders at the genetic level, the principal of gene delivery has been well 
discussed and established [104-106]. Classical gene delivery mainly includes two 
systems: viral vectors and non-viral delivery systems. Viral delivery systems are far more 
efficient than other gene delivery systems. However, many obstacles such as innate 
immunity issues, and the potential of oncogenicity and mutation insertion risk limits its 
wide application [104]. Non-viral delivery systems are considered to be safer and 
immunologically protective [104].  
The choice of delivery system also depends on the differences of RNAi effectors, which 
includes long dsRNAs, shRNA and siRNA.  
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Long dsRNAs (200-500 nucleotides) can be injected into animals or (in most cases) into 
blastocysts to achieve widespread stable incorporation and expression in multiple cells 
and tissues, delivered by bacteria, expressed as transgenes, or delivered into cultured cells 
by transfection or bathing cells in dsRNA-containing medium. In endoribonuclease-
prepared siRNA methods, long dsRNA are used to produce a pool of small siRNAs that 
are then transfected into cells [107]. However, long dsRNAs are usually not used in 
mammalian systems since they trigger an unwanted interferon response that masks gene-
specific effects [67].  
ShRNAs are usually expressed from plasmids or virus based expression vectors. The first 
studies applying shRNAs in vivo used plasmid DNA [108]; Most subsequent studies, 
however, have focused on the use of viral vectors. The choice of viral delivery system 
usually depends on the cell type under investigation and on the need for short- or long-
term shRNA expression. Until now, most shRNA-based studies have employed the 
standard viral vector expression systems used in traditional gene therapy [86].  
siRNAs play an entirely different role in the transcription and expression process for 
short-term non-viral nucleic acid delivery [109]. siRNAs are potent and specific 
inhibitors of gene expression and are being used as a new technology for drug target 
validation, study of functional genomics, design of transgenes and as promising 
therapeutic agents for diseases with a genetic etiology [110].  
In vitro, siRNAs are usually transfected into cultured mammalian cells by standard 
physico-chemical methods, such as methods based on cationic lipids, cationic polymers 
or electroporation. Different cell systems might have different efficacious transfection 
methods [111].  
In vivo delivery of siRNA has many challenges. First, naked siRNAs are not stable in 
serum. They are either easily degraded by RNAase or easily removed by renal clearance, 
which results it a short half-life in serum. Therefore, some investigators tried to 
chemically modify the sugars, the backbone or the base of oligoribonucleotides to 
stabilize the siRNA molecule without impairing capacity to specifically and efficiently 
knock down the target [112, 113]. However, the cell membrane is hydrophobic and 
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negatively charged, which creates a barrier by repelling the hydrophilic and negatively 
charged polymers. Additionally, siRNAs only transiently silence the intended gene 
product when they enter the cell since the concentration decreases with each cell division 
[46]. Nanoparticle carriers have the ability to prevent siRNAs from intravascular 
degradation and to deliver them into cells safely and efficiently and with lowered risk of 
degradation and/or interaction with non-target molecules en route to target cells and 
tissues. However, in the bloodstream, nanoparticles will encounter many non-target 
molecules and non-target cells, including monocytes, leukocytes, platelets and dendritic 
cells. Nanoparticle uptake by immune cells can lead to subsequent (and potentially 
undesirable) immune responses. Moreover, the physical and chemical properties of the 
nanoparticle surface, such as size and surface charge, may also lead to haemolysis, 
thrombogenicity and complement activation, resulting in altered biodistribution and 
potential toxicity [114].    
Second, to achieve effective RNAi application in vivo, barriers to entry into tissues and 
targeting of intracellular compartments must to be overcome. Nanoparticles for siRNA 
are ranged from 1nm to 1000 nm in diameter. However, for safe and effective delivery of 
RNAi to targeted mRNAs, it is now clear that nanoparticles >100 nm in diameter are 
likely to be trapped by cells of the reticuloendothelial system (RES) in the liver, spleen, 
lung, and bone marrow when intravenously injected in vivo, leading to RNAi effector 
molecules by activated monocytes and macrophages. Thus, nanoparticles of around 100 
nm in diameter are thought to be optimal for avoiding RES clearance [115].  
Third, cell entrance and endosomal escape are crucial issues for effective siRNA delivery. 
Many nanoparticles enter cells by endocytosis [116]. As soon as the nanoparticle is 
endocytosed by cells, it begins travel in early endosomal vesicles. The early endosome 
will then fuse with sorting endosomes, which transfer their contents to late endosomes. 
The late endosomes maintain a low pH through the activity of membrane-bound proton-
pump ATPases. Late endosomes will relocate to lysosomes, which are acidic (~pH4.5) 
and contain nucleases that degrade RNA [117]. Thus, if the nanoparticle is not able to 
escape from the endosome, siRNAs will not be released into the cell cytoplasm and 
function as RNAi effectors. Mechanistic approaches designed to promote endosome 
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escape involve the use of fusogenic lipids, fusogenic peptides, photosensitive molecules, 
pH-sensitive lipoplexes, and pH-sensitive polyplexes. Fusogenic lipids promote 
endosomal release by increasing the interactions between liposomal and endosomal 
membranes. pH-sensitive materials use proton “sponge” effects, in which the delivery 
material induces an influx of chloride ions and subsequent osmosis, resulting in 
endosomal rupture and the release of endosomal contents [117].  
Fourth, the intracellular factors have drawn the majority of research efforts; less 
commonly studied extracellular factors in the tumour microenvironment could be more 
important. For example, in the targeted delivery of cancer cells, nanoparticle must 
exravasate and move through the ECM to reach the cancer cells. This complex tumour 
microenvironment poses a challenge for accumulating therapeutic drug concentrations in 
target cells [118]. The biological and physical properties of the ECM could result in the 
unpackaging of nanoparticles and the release of their contents prior to delivery to target 
cells [119]. These dynamic factors in vivo stress a limitation of in vitro testing that are 
inherently static conditions that do not reflect dynamic forces in vivo and, therefore, may 
inaccurately predict in vivo effectiveness. To minimize this disparity three dimensional 
models could be useful in imitating the ECM barriers for nanoparticles delivery [120]. 
The immune system is also an important extracellular barrier. Particles deviating from an 
overall neutral electrical charge (i.e. cationic or anionic) are more easily phagocytosed  
by macrophages like Kupffer cells in liver and dendritic cells in lymph nodes than those 
in neutral nanoparticles [114]. Besides macrophages, neutrophils can also function as 
extracellular traps for nanoparticles [115, 121, 122].   
 
1.4.1 Topical siRNA delivery  
1.4.1.1 Skin structure 
Skin has a surface area that approximately spans over 2 m2 in the average adult. It shields 
the body from the environment and protects the body from toxic chemicals, ultraviolet 
radiation, microorganisms, and mechanical trauma. It is of vital importance in preventing 
water and electrolyte loss. Skin is also an important organ for excretion of certain 
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substances, immunological sensing, and in regulating body temperature by direct 
radiation and secretion of water [123, 124] .  
There are three major layers of skin: epidermis, dermis, and underlying subcutaneous 
tissue (Figure 1-2). The barrier function of skin relies mainly on the epidermis. The 
epidermis is composed of keratinocytes, including the stratum basale (basal cell layer), 
stratum spinosum, stratum granulosum, and stratum corneum (from body to surface, in 
that order). Immediately under the epidermis is the basal lamina, which supports the 
epidermis. The dermis contains capillary and lymphatic vessels, and skin appendages 
such as nerve endings, hair follicles, sebaceous glands, and sweat glands. Hair follicles 
and sweat ducts open directly into the environment at the skin surface and provide the so-
called appendageal route of skin permeation, which is very important for topical drug 
delivery. Below the dermis is the subcutaneous layer which provides insulation, 
protective padding, and energy storage [125, 126].  
 
1.4.1.2 Advantages and challenges of topical delivery of siRNA 
Increased understanding of the components of signaling pathways, coupled with 
generation of small molecules and antibodies capable of interacting with those 
components, has profoundly influenced treatment of inflammatory diseases, cancers, 
genetic disorders, and diseases in skin [127-129]. However, most protein-based 
therapeutics are costly, have limited targeting ability, and can lead to systemic toxicity 
when applied systemically [130, 131]. Topical delivery of siRNA is particular attractive 
for treatment of skin disorders, because proteins larger than a few hundred daltons are not 
easily delivered into skin, and high concentrations of proteins are necessary for cutaneous 
effect [132]. SiRNA has great potential for treatment of skin disease by specifically 
inhibiting expression of one or several proteins. Topical delivery of siRNA allows 
preferential, direct targeting of skin cells [94]. Cutaneous delivery of siRNA is locally 
restricted to the affected skin area, the systemic dose of topically applied siRNA is 
significantly less than for intravenous administration, and topical delivery can lead to  
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Figure 1-2 Skin structure.  
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high local cutaneous dose (assuming good skin penetration). Generally speaking, 
molecules less than 500 Da have high penetrating capacity [133], As result, systemic 
toxicity is reduced [134]. Moreover, the region to which siRNA is applied can be visually 
monitored or easily biopsied if monitoring of therapeutic effects and/or pathological 
analysis is required. Also, topically siRNA delivery is user-friendly. Three siRNA 
topically-delivered drugs are undergoing clinical trial, including siRNA eye drops for the 
treatment of ocular hypertension and glaucoma (from Sylentis, Inc.), an inhaled siRNA 
drug for asthma (from ZaBeCor, Inc.), and an siRNA drug for respiratory syncytial virus 
(RSV, from Alnylam, Inc.)ccz delivered to human patients by nebulizer and nasal spray 
[126]. However, the cutaneous delivery of siRNA still faces many obstacles. The 
penetration of oligonucleotides through the epidermis barrier becomes the predominant 
major technical challenge in cutaneous delivery of siRNA [135].  
In vivo delivery of siRNA is challenging, since siRNA itself has difficulty being absorbed 
by skin and it is relatively unstable and subject to degradation prior to interaction with 
target RNA [136]. Moreover, siRNA is negatively charged and relatively large: this leads 
to repulsion by cell membrane (also negatively charged) and difficulty in being taken up 
by cells through pores in plasma membranes. Regardless of that, keratinocytes have the 
ability to take up unmodified DNA or siRNA in a mouse skin model [123, 125, 137-139]. 
This is important in that it suggests that cutaneous gene therapy is feasible. However, 
keratinocyte uptake of nucleic acids without modification (or encapsulation in delivery 
vehicle) requires intradermal injection, which is not user-friendly and is painful when 
repeated injection is necessary. Moreover, injection can applied to only a small area of 
skin for each injection site, which makes it limited for application to larger skin areas or 
whole body skin diseases. Thus, penetration-enhancing techniques are needed for 
cutaneous topical siRNA delivery.  
Stratum corneum (SC) in epidermis is the major barrier to cutaneous siRNA delivery. 
The SC is composed of terminally differentiated nonnucleated keratinocytes (also called 
corneocytes). These cells run perpendicular to the skin surface and are packed in tight 
columns. The cellular matrix between corneocytes is composed of hydrophobic non-polar 
lipids. Those lipids are assembled into lamellar stacks to form a very densely packed 
23 
 
structure [126], that is resistant to permeation by topically-applied siRNA. Moreover, the 
dense network of polysaccharides and fibrous proteins also creates a barrier for siRNA 
penetration. Since the basal membrane is an electron-dense adhesion structure, even 
topically-delivered siRNA that passes successfully through the barrier of the stratum 
corneum has difficulty in entering cells and reaching reaching target RNA [127].  
In my study, I generated a chemical siRNA transdermal enhancer composed of three 
chemical reagents selected to assist in moving siRNA through multiple barriers in skin 
and skin cells to reach target mRNA. We applied the new cutaneous delivery reagent and 
siRNA complex to treatment of allergic contact dermatitis (ACD). 
 
1.4.2 Lipid based siRNA delivery  
Currently, most in vivo studies use synthetic lipid-based siRNA carriers with or without 
modifications to the carriers themselves. The beneficial properties of liposomes as drug 
delivery vectors were first recognized in the 1970s, spurring an increase in 
biopharmaceutical research on this area that has steadily increased since then [140-142]. 
Liposomes are spherical soft matter particles consisting of one or more bilayer 
membrane(s), and are most commonly composed of phospholipids encapsulating a 
volume of aqueous medium. Liposomes boast many advantages as a drug carrier such as 
good biocompatibility, biodegradability, low toxicity and structural variability [143].  
Cationic liposomes in particular serve as good candidates for the delivery of siRNA. First, 
properly designed cationic liposomes have demonstrated potent transfection efficiencies 
both in vitro and in vivo [144]. Cationic liposomes can tightly compact and encapsulate 
siRNA through electrostatic interactions, thus protecting the siRNA from circulation 
dynamics and nuclease degradation while traveling in the vasculature [145, 146]. Second, 
the size of cationic liposomes can be manipulated through extrusion [147], preventing 
excretion in the urine when too small or blocking of the microcirculation when too large. 
Particle size is also of vital importance in optimizing ability to overcome the tissue 
barrier, transfecting cells efficiently, and regulating surface properties. Third, the 
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structural variability of liposomes allows a variety of modifications, such as conjugation 
of ligands or polymers onto the surface for targeting delivery, and addition of other 
modulator molecules to the interior compartment of liposomes to improve transfection 
[144]. The cationic surface of the liposome helps to shield the electrostatic repulsion 
between the cell membrane and naked nucleic acid, aiding in uptake. The cationic 
liposome is at least 1000 fold more efficient in delivering encapsulated nucleic acids than 
delivery of naked nucleic acids [148]. 
 
1.4.2.1 Mannose liposome delivery 
Mannose receptors are highly expressed in cells of the immune system (i.e., macrophages 
and DCs, especially in professional APCs [149-153]. Transmembrane mannose receptors 
mediate endocytosis, function as antigen capture receptors and are involved in antigen 
capture and presentation [154-156]. The preferential expression of mannose receptors in 
the cells of the immune system makes it a promising target for various therapies, 
including chemotherapeutic treatments targeting macrophages, vaccines against DCs 
[157], and gene delivery to APCs. Mannosylation has been successfully applied to 
vaccination and, in fact, several constructs are currently undergoing clinical trials [158].  
Mannosylated particulates are formed by the association of the mannose derivative to a 
carrier (liposome, nanoparticle, etc.). The mannose derivative acts as a targeting agent 
whereas the particulate or carrier acts as a reservoir for the therapeutic agent. Their 
particulate nature allows these particles to be engulfed by phagocytic APCs and 
mannosylation will further improve their phagocytosis mediated by specific receptors.  
Compared to other carrier delivery systems, liposomes offer multiple advantages for drug 
delivery, including their biocompatibility, biodegradability and safety. Mannosylated 
liposomes are considered to be promising non-live vectors for targeted delivery purposes. 
In fact, mannosed liposomes have been successfully applied in APCs targeting DNA 
vaccine against cancer [159] and protein vaccine delivery against N. meningitides [160]. 
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1.4.2.2 Folate liposome delivery 
Folic acid is a water-soluble B vitamin essential for the de novo synthesis of DNA and 
one carbon transfer reactions in cells [161]. In vivo, folate receptor (FR) has high affinity 
for folate.  
FRs, also known as folate-binding proteins (FBPs), are N-glycosylated proteins with high 
binding affinity to folate. FRs include at least four isoforms: , ,  / γ ′and δ. The 
affinities of folic acid for the FRs are: FR-α , Kd~ 0.1 nM [162]; FR-β , Kd ~1 nM [163]; 
and FR-γ , Kd ~ 0.4 nM [164]. Functional FR expression is low or absent in most normal 
tissues, with FR-α expression limited to the luminal surface of certain epithelial cells and 
inaccessible to blood circulation [165]. In contrast, many malignant cancers such as those 
arising in brain, kidney, lung, and breast and, in particular, in epithelial carcinomas such 
as ovarian cancers, consistently and uniformly express high levels of FR-, which is 
accessible to circulating blood [161, 166]. 
FR-β is a differentiation marker in the myelomonocytic lineage during neutrophil 
maturation [167] and is amplified in activated monocytes and macrophages [168]. FR-β 
is functionally expressed in certain cancers, such as chronic myelogenous leukemia 
(CML) and in 70% of acute myelogenous leukemias (AML) [111, 169].  
The soluble FR-/γ ′ is expressed mainly at low levels in certain haematopoietic cells, 
and has a relatively insignificant role in FR-targeted drug delivery. 
FR-δ is expressed on regulatory T cells and has recently been discussed as a potential 
therapeutic target [170]. 
The frequent overexpression within tumours and highly restricted distribution in normal 
tissues suggest that both FR- and - can potentially be exploited as a tumour-specific 
cell surface marker that can be used in the targeted delivery of cancer therapeutics [161, 
171].  
Folate-based targeting systems have already been successfully applied as a therapeutic 
agents and imaging agents [172, 173]. Folate liposomes have good biocompatibility, 
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biodegradability, and safety. Further, liposomes are able to accumulate within tumour 
tissue due to the passive accumulation of colloidal macromolecules of approximately	40 
kDa and above, which contributes to the EPR [174]. The accumulation of liposome in 
tumour tissue could be further improved through the use of receptor targeting moieties 
(i.e., folate) that are either conjugated to the surface of liposomes after encapsulation or 
siRNA, or are attached to lipids that become incorporated within the liposomal bilayer 
during liposome assembly [175].  
Conjugation of folate to a lipid-PEG linker through theγ-carboxyl [171, 176] of folate 
serves to both anchor the folate molecule to liposomes and maintain its affinity to the FR. 
Therefore, liposomes that included folate-conjugated lipids are considered to be 
promising non-live vectors for targeted delivery of therapeutic molecules to tumours. 
Two different disease models (ACD and melanoma) were used to examine the three 
targeted RNAi-based therapies described in this thesis.  
 
1.5 Introduction to allergic contact dermatitis 
Contact dermatitis is an eczematous skin reaction caused by direct and usually repeated 
exposure to harmful objects or chemicals. It is one of the most common skin diseases and 
may vary from slight hyperkeratosis and small fissures to extensive redness, swelling and 
scaling [177]. There are three types of contact dermatitis: ACD; irritant contact dermatitis, 
and photo-contact dermatitis. ACD is known the most prevalent form of immuno-toxicity 
in humans. 
ACD is the consequence of an undesired immune reaction to hapten contacting the skin. 
It is a type IV delayed hypersensitivity [178, 179]. Its initiation needs the development of 
the effector T cell response against the hapten, which results in the skin inflammation. 
There are two phases during this process: the sensitization phase and the elicitation phase.  
The sensitization phase begins with contact between skin and hapten and leads to 
generation of hapten-specific T cells in lymph node (LN). Those hapten-specific T cells 
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then return to skin. Haptens induce sensitization through two distinct properties: intrinsic 
pro-inflammatory properties, and by binding to amino acid residues in self-proteins to 
generate new antigenic determinants in skin [180]. When haptens induce sensitization 
through their pro-inflammatory properties, they activate innate immune activity in skin 
tissue and deliver signals which induce the migration and maturation of cutaneous DCs. 
When haptens induce sensitization by binding to amino acid residues to modify self 
proteins, the haptens or haptenated proteins are loaded into cutaneous DCs and are 
expressed as haptenated peptides in the groove of major histocompatibility complex class 
I (MHC I) and class II molecules of those cells. Those DCs will migrate from the skin to 
regional lymph nodes (LNs) where they are capable of priming CD8+ and CD4+T cells 
for recognition of those antigens. T cells will then proliferate and migrate out of LNs and 
circulate between the lymphoid organs and the skin. The sensitization step lasts 10 to 15 
days in man, and 5 to 7 days in the mouse.  
In the elicitation phase, the challenge with the same hapten in the sensitized individuals 
leads in the apparition of ACD. When haptens diffuse into the skin and are taken up by 
skin cells that express MHC I and II/haptenated peptide complexes, hapten-specific T 
cells are then activated in the dermis and epidermis and trigger the inflammatory process 
responsible for the cutaneous lesions. Understanding of ACD derives from experiments 
undertaken in animal contact hypersensitivity (CHS) model. CD8+ cytotoxic T 
lymphocytes are the main effector cells of CHS and they are recruited early after 
challenge. The elicitation phase of CHS takes 72 hours in man, and 24 to 48 hours in 
mouse. The inflammatory reaction persists for only a few days and then rapidly decreases 
following down regulatory events [178].  
 
1.5.1 The role of TNFα and MyD88 in contact dermatities 
TNFα is a cytokine known to be involved in systemic inflammation. The primary role of 
TNFα is in the regulation of immune cells [181]. It activates neutrophils, up-regulates 
expression of the endothelial adhesion molecules, increases capillary permeability and 
has a direct cellular toxic effect. In the CHS model, the release of TNFα can activate 
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local endothelial cells and facilitate T cell recruitment [181, 182]. Among the mediators 
of inflammation, TNFα is one of the most important factors and plays a major role in the 
elicitation of CHS [183]. TNFα that released by mast cells and platelets is important in 
initial recruitment of T cells [184, 185].  
The MyD88 is critical for signaling from all Toll like receptors (TLRs) except TLR3 
[186], and is expressed in a variety of human and murine tissue albeit at varying levels 
[187]. Its involvement in the Toll/interleukin-1 receptor (TIR) signaling pathway, results 
in NF-кB activation, cytokine secretion and and inflammation. MyD88-deficient mice are 
unable to mount a CHS response [188]. 
Most information about ACD has been acquired using a mouse model of induced CHS 
[183]. In this study, we use this model and 1-fluoro-2, 4-dinitrobenzene (DNFB)-induced 
CHS in mice, which is well-established as a model inducer of CHS to model ACD [189].  
 
1.6 Introduction to melanoma  
Melanoma is the sixth most common cancer and the human malignancy with the highest 
recent rise in incidence (a rise that continues) [86]. Melanomas can arise at any 
anatomical site occupied by monocytes. However, cutaneous melanoma, which develops 
from epidermal skin melanocytes, represents the most common site of origination. In this 
study, I focus on cutaneous melanoma. Cutaneous melanoma is the deadliest form of skin 
cancer and it is arguably one of the most aggressive malignancies overall. Classically, the 
pathological workup for melanoma includes description of the growth pattern and 
measurement of vertical thickness (also called Breslow) [131]. Superficial spreading 
(nodular, acral lentiginous, lentigo maligna, lentiginous and desmoplastic) are all 
included in histological growth patterns. Although prognosis depends on lots of data, 
such as ulceration and penetration through cutaneous layers or mitotic rate, Breslow 
thickness is the critical prognostic parameter.  
In 2009, the American Joint Committee on Cancer (AJCC) updated melanoma TNM 
classification categories [132] (Table 1-1, 1-2) . Mitotic rate and ulceration become  
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Table 1-1TNM classification AJCC 2009 
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TNM classification AJCC 2009 [132] 
T Thickness Ulceration, Mitotic rate 
T1 Up to 1 mm a. No ulceration and <1 mitosis/mm2
b. Ulceration or >1 mitosis/mm2 
T2 01 - 2 mm a. No ulceration  
b. Ulceration 
T3 1-4 mm a. No ulceration 
b. Ulceration 
T4 >4 mm a. No ulceration 
b. Ulceration 
N Number of nodes Tumour burden 
N1 1 a. Micrometastasis 
b. Macrometastasis 
N2 2-3 a. Micrometastasis 
b. Macrometastasis 
c. In transit satellites but no distant 
nodes 
N3 >3 or in transit satellites with metastatic 
nodes 
M 
M1a Distant soft tissues, normal LDH 
M1b Lung, normal LDH 
M1c Other viscera or elevated LDH 
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Table 1-2AJCC 2009 staging classification 
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AJCC 2009 staging classification [132]  
IA T1a N0M0 
IB T1b 
IIA T2bT3a 
IIB T3bT4a 
IIC T4b 
IIIA T1a-T4a N1a-N2a 
 
N+M0 
IIIB T1b-T4b N1a-N2a 
T1a-T4a N1b-N2b-N2c 
IIIC T1b-T4b N1b-N2b-N2c 
Any N3 
IV Any M1 M1 
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important with tumour thickness in patients with localized melanoma. The N category 
depends on the number of positive lymph nodes, tumour burden, and ulceration in 
patients with metastatic lymph nodes. Among patients with localized disease, it is 
important to define a subgroup of patients with a greater rate of relapse. This population 
receives adjuvant therapy [131].  
Patients with stage IIB, IIC or III disease, such as those with ulcerated tumours with 
Breslow thickness 2-4 mm, tumours with Breslow thickness >4mm, or tumours with 
positive lymph nodes are considered to be at high risk [131]. Among those at high risk, 
differences in prognosis can be marked. For example, while patients with stage IIIA 
disease have a ten-year overall survival rate of over 70%, stage IIIB and IIIC have only 
40% and 25% ten year survival rates, respectively. Stage IV survival rate depends on 
tumour burden and the location of metastases. While average survival in this stage is 6-7 
months, less than 10% of the patients survive longer than one year [131]. There is 
promise that this survival rate will be increased by application of inhibitors of v-Raf 
murine sarcoma viral oncogene homolog B1 (B-RAF) in the future [132]. For several 
decades progress in melanoma treatment has been slow. However, new staging 
classification, insights into the patterns of relapse at early stage, better understanding of 
the molecular biology underlying the malignant characteristics of melanoma, and 
development of new drugs for treatment of advanced diseases, have all increased 
progress. Effort has now focused on identification of altered gene pathways (knowledge 
of which is known to be helpful in diagnosis) and the development of new therapeutics 
[131]. The identification of mutant B-RAF as a major driver of melanoma progression 
highlighted targeting of B-RAF as a therapeutic opportunity in treatment of melanoma 
[131]. 
Several years following discovery of B-RAF mutations in melanoma, the first selective 
inhibitor (vemurafenib) entered clinical trials. However, although tumour regression 
during and after the early course of the therapy was observed, resistance to therapy 
emerged during subsequent treatments. The response duration ranged from 2 to >18 
months. Current research focuses on mechanisms underlying resistance to B-RAF [190]. 
Because siRNA therapy targets a major mechanism underlying resistance to targeted 
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agents (i.e., target overexpression), it’s use may be desirable to help avoid resistance that 
can develop following treatment with small molecule inhibitors that target specific 
proteins without reducing mRNAs available to mediate increased synthesis of additional 
target molecules. Moreover, targeting mRNA sequences has increased potential to 
enhance target specificity and reduce off-target effects.  
Melanoma is characterized as one of the most immunogenic tumours due to the presence 
of tumour infiltrating lymphocytes in resected melanoma, occasional spontaneous 
regressions, and clinical responses to immune stimulation. The immunogenicity of 
melanoma has led investigators to study novel immune strategies to overcome tumour 
immune evasion [191]. One mechanism relates to indoleamine 2, 3-dioxygenase (IDO), a 
molecular express on APCs could block T cell activation and induce T cell apoptosis, 
generating more regulatory T cells and thereby create a tolerance immune environment 
for tumour progress. In 2007, dextro-1-methyltryptophan (D-1MT), a classical IDO 
inhibitor, entered clinical trials. It is able to influence complex culture systems, in which 
many proteins take place in immunoregulatory role. However, it observed that D-1MT 
did not inhibit purified IDO [130]. A paradox has emerged that the immunoregulatory 
role of D-1MT needs IDO expression to function whereas its ability of inhibiting purified 
IDO is weak. The mechanism of why D-1MT needs IDO expression in mice to function 
and its effect in clinical trials still need to be further studied. As the inhibitory activity for 
both of the isomers (D-1MT and L-1MT) of 1MT are weak, it is questionable whether 
they will ever be useful in the clinic as IDO inhibitors. Gene silencing by therapeutic 
nucleic acids, particularly siRNA, is a promising way of specifically inhibiting the 
expression of a protein with potential in cancer therapy [192].  
Two difference approaches, in which two molecules that have great potential of being 
used as therapeutic molecular in the future have been targeted in our study: IDO and B-
RAF.  
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1.6.1 Introduction to IDO 
Cutaneous melanoma arises from the largest organ with immune function, the skin. 
Neoplastic cells can bypass immune surveillance by influencing and inhibiting immune 
cell function at virtually all stages of tumour development, including initiation, 
promotion/progression, and tumour invasion and metastases. IDO expression in DCs has 
been identified as a property of those cells that decreases DC function and contributes to 
immune tolerance of tumours. IDO is the first and rate-limiting enzyme of tryptophan 
catabolism in the kynurenine pathway (Figure 1-3), thus depleting tryptophan and 
reducing T cell growth and activity [193]. 
 
1.6.1.1 Tryptophan and kynurenine pathway 
L-Tryptophan (L-Trp) is an essential metabolite in mammals and the least abundant of all 
essential amino acids (Figure 1-3). It must be metabolized through several strictly 
controlled pathways to form biologically active compounds [194]. These compounds 
include: aminergic neurotransmitter serotonin (5-hydroxytryptamine, 5-HT), 
neurohormone melatonin, several neuroactive metabolites of melatonin, products of the 
kynurenine (KYN) pathway, and tryptamine [195]. Among the several metabolic 
pathways for tryptophan, the kynurenine pathway is the main route of non-protein 
metabolism (Figure 1-3). Under normal circumstances, protein catabolism is balanced by 
protein synthesis so that the protein-related pool of tryptophan remains fairly constant. 
While the protein related pool of L-Trp is constantly balanced, approximately 99% of 
dietary intake L-Trp is processed by the kynurenine pathway of catabolism [196] making 
its importance vital in L-Trp metabolism.  
In the kynurenine pathway, IDO and tryptophan 2,3-dioxygenase (TDO) are cytosolic 
heme dioxygenases that catalyze the oxidative cleavage of the C2-C3 bond of the indolic 
ring of L-Trp. This reaction is the first and rate-limiting step of the kynurenine pathway 
of tryptophan catabolism [197-199]. 
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Figure 1-3 Schematic representation of kynurenine pathway 
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After the transformation of tryptophan into kynurenine, the action of enzymes along the 
kynurenine pathway will then convert kynurenine into other catabolites [200, 201]. 
Kynurenine 3-hydroxylase (kynurenine 3-monooxygenase) converts KYN to toxic3-
hydroxyky-nurenine (3-HK) [198]. One of the end products is quinolinic acid (QUIN), an 
agonist of the N-methyl-D-aspartate (NMDA)-sensitive glutamate receptors [202]. 
Another arm of the kynurenine pathway produces kynurenic acid (KYNA), which is an 
endogenous antagonist of NMDA receptors. Moreover, KYNA can noncompetitively 
block the activity of α7-nicotinic acethylcholine (α7-nACh) receptors [203-205]. 
Expression analysis indicates that the G protein-coupled receptor (GPCR) GPR35 is 
selectively present in immune and intestinal tissues and is also a receptor of KYNA [206]. 
The KYN pathway has been widely studied in relation to neurodegenerative or 
excitotoxic insults [207]. KYNA protects the central nervous system in excitotoxic 
neurological diseases [198, 208] while quinolinic acid can act as a neurotoxin [209-213]. 
Various physiological and pathological processes are related to ‘‘kynurenines’’, the 
collectively term of metabolites of kynurenine pathway [214].  
 
1.6.1.2 IDO in the immune system and tumour immunity 
Interest in the role of kynurenines in immune function has grown. Stone and coworkers 
[209, 215] demonstrated that QUIN might play an important role in normal 
immunosurveillance. In recent years, the role of kynurenine pathway in both the innate 
and adaptive immune responses has been widely studied, and tryptophan metabolism and 
kynurenine production reflect a crucial interface between the immune and nervous 
systems [216].  
In mammals, it is noteworthy that excess dietary tryptophan is not catabolized by IDO 
through the kynurenine pathway. Tryptophan dioxygenase and nicotinamide adenine 
dinucleotide levels are not maintained by synthesis, but by salvage. It implies that 
tryptophan levels are maintained for purposes other than simply satisfying requirements 
for protein synthesis. This was revealed by Munn and his colleagues in 1998, who also 
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showed that IDO suppresses maternal T cell activity against embryonic tissues by 
catabolizing tryptophan [217].  
Since then, the role of IDO as a crucial enzyme in kynurenine pathway, and in 
immunoregulation during infection, pregnancy, autoimmunity, transplantation and 
neoplasia has been widely investigated [218, 219]. Recently, a novel enzymatic isoform 
of IDO was described and termed indoleamine 2,3-dioxygenase-2 (IDO-2) (Ball et al. 
2007, 2008). IDO and IDO-2 have a high degree of sequence homology (43% identity). 
IDO-2 is predominantly expressed in murine kidney, liver, and in the male and female 
reproductive system where, similar to the activity of IDO, it catalyzes oxidative cleavage 
of a broad range of indole-bearing substrates [195, 220, 221]. 
In fact, the details of how IDO modulates the immune system are still not completely 
clear. Two main theories have been proposed: the first pertains to starving cells of 
tryptophan, while the other revolves around tryptophan metabolites. In the tryptophan 
starvation theory, IDO has an effect on mammalian T cells similar to its effect in bacteria 
[222, 223]. That is, tryptophan depletion induces cell cycle arrest in mammalian T 
lymphocytes [220, 224] and makes these cells more vulnerable to apoptosis [225]. An 
IDO-induced decrease in tryptophan concentration results in cell cycle arrest and anergy 
(a state of unresponsiveness in peripheral T cells)[226, 227]. 
The tryptophan metabolite theory, on the other hand, is based on the observation that 
certain downstream tryptophan-derived metabolites, mainly kynurenine, 3-
hydroxykynurenine, 3-hydroxyanthranilic acid, and QUIN are toxic to lymphocytes [228]. 
These molecules cause cell cycle arrest and apoptosis [229, 230], and can induce 
differentiation of naive CD4+ T cells into immunosuppressive regulatory T cells 
(Tregs)[231]. 
Much work has gone into understanding the relationship between IDO and tumour 
immunity. IDO+ plasmacytoid dendritic cells (pDCs) are present in tumour lesions and in 
tumour-draining lymph nodes (TDLNs) at sites of tumour growth in mice and humans. 
Melanoma patients with abnormal accumulations of IDO+ cells with DC markers in 
human sentinel LN draining sites had poorer clinical outcomes [98, 232]. 
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IDO also promotes tumour development through its effect on T cells. Cytotoxic T-
Lymphocyte Antigen 4 (CTLA4+) Tregs ligate B7 on pDCs, maintaining IDO activity in 
pDCs [233-235]. Blockade of CTLA4/B7 interactions had a significant impact on the 
reduction of IDO enzymatic activity and Treg activation. IDO-activated Tregs mediated 
suppression via a unique and distinctive mechanism that depended on intact programmed 
death (PD)-1/PDL-1 signaling, which was not dependent on Interleukin 2 (IL-2), IL-10 or 
transforming growth factor beta (TGF-β) [236, 237].  
Increased expression of IDO through a pathway involving signal transducer and activator 
of transcription 1 (STAT1) and nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB) caused the loss of bridging integrator (Bin1)[238]. Bin1 loss is evident in 
various cancers [219, 239], including those arising in breast [240], prostate [241], colon, 
and lung [242]. Therefore, there is a link between loss of Bin1 and increased levels of 
IDO. This link is tentative, however, and requires further investigation to be confirmed. 
We used mannosed-liposome and IDO siRNA complexes to silence IDO expression in 
DCs in melanoma-bearing mice. We hypothesized that this strategy would reinstall anti-
tumour immunity and restrict melanoma xenograft growth through host mouse immune 
activity.  
 
1.6.2 Introduction to B-RAF 
The RAS gene family harbours some of the most frequently-detected genetic alternations 
in epithelial cancers and plays a central role in both normal and malignant cell growth 
[243]. The first identified downstream effectors of RAS were the RAF serine/threonine 
kinases [244-246]. There are three members in RAF family; A-RAF, B-RAF and C-RAF 
(or RAF1), which have a high degree of homology in three conserved regions. Each 
kinase has a RAS-binding domain and cysteine-rich domain that mediates interaction 
with guanosine triphosphate (GTP)-bound RAS [247, 248]. In association with RAS, 
RAF is recruited to the plasma membrane and the inhibitory intramolecular interaction of 
the RAF catalytic domain with the NH2 terminus is diminished, leading to 
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phosphorylation of sites located in the catalytic loop of the activation domain (Thr599 
and Ser602 of B-RAF) [249]. Although all RAF isoforms are similar in these initiating 
events, additional activation outside the catalytic domain (Tyr340, Tyr341, and Ser338 in 
C-RAF) is required for full activation of A-RAF and C-RAF.  
Since oncogenic B-RAF mutation was discovered in 2002, it stands as one of the most 
powerful affirmations of the transformative potential of systematic cancer genome 
characterization [250, 251]. Amino acid residues corresponding to sites of oncogenic 
mutation in the B-RAF gene are either substituted with aspartic acids (Asp448 and 
Asp449) or seem to be constitutively phosphorylated (Ser446) in tumour cells [252]. 
These changes highlight key events that reveal that B-RAF is the most important 
physiologic mitogen-activated protein kinase (MAPK)/extracellular signal-regulated 
kinase (ERK) kinase (MEK) activator. It is reported that MEK/ERK activation was 
significantly disrupted in B-RAF -/- embryonic fibroblasts [253] but not in cells lacking 
A-RAF or C-RAF [254], which further supports a predominant role for B-RAF as an 
important MEK activator. Taken together, these data provide a mechanistic explanation 
for the observation that B-RAF mutations, but not comparable mutations in the other 
RAF proteins, are thought to underly the propensity of B-RAF for MEK/ERK activation.  
B-RAF mutations have been reported to be present in over 70% of melanomas [255]. The 
mutations are also found in premalignant atypical or dysplastic nevi, implicating B-RAF 
activation as an initiating event in tumourigenesis [248, 256]. While there was a lower 
frequency of B-RAF mutations in liver, pancreas, nonsmall cell lung cancer, glioma, and 
acute myelogenous leukemia, a high frequency of B-RAF mutations were detected in 
papillary thyroid carcinomas, serous ovarian cancers, and colorectal serrated 
adenocarcinomas. Nearly 90% of B-RAF mutations are a T1799A transversion in exon 
15 that results in Val600Glu (V600E) amino acid substitution, which leads to constitutive 
kinase activation [257]. Interestingly, less than 1% of the melanomas carry both B-RAF 
and RAS mutations (the latter occurring in more than 10% of melanomas), which 
provides strong genetic evidence of direct RAS/B-RAF signaling pathway in this tumour 
type. Moreover, even in cancers without RAS or B-RAF mutations, increased 
RAF/MEK/ERK signaling can arise from other mechanisms [258, 259] including 
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increased signaling from epidermal growth factor receptor (EGFR), human epidermal 
growth factor receptor 2 (ERBB2 or HER2), platelet-derived growth factor receptor 
(PDGFR), hepatocyte growth factor receptor (MET), and vascular endothelial growth 
factor receptor (VEGFR), and loss of downstream negative regulators such as MAPK 
phosphatase 3 (DUSP6) and RAF kinase inhibitor protein. Therefore, it is thought that 
the majority if human tumours, not only those with RAS or B-RAF mutations, engage the 
RAF/MEK/ERK signaling cascade. In general, B-RAF is an attractive therapeutic target 
[260]. 
In our study, we used a lipid-based tumour-targeting siRNA delivery system and a local 
topical siRNA delivery system to delivery B-RAF siRNA to cutaneous melanoma. We 
hypothesized that these delivery systems can preferentially target tumour cells and 
achieve B-RAF silencing in cutaneous melanoma, thereby restricting tumour growth. 
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Chapter 2  
2 A novel topical delivery reagent for siRNA-based 
contact dermatitis therapy: preventing allergic 
dermatitis by topical administration of MyD88 and 
TNFα siRNAs 
2.1 Summary 
Topical delivery of siRNA is an attractive strategy to treat skin disorders that are resistant 
to drug treatment, including allergic contact dermatitis (ACD). Topical siRNA has the 
potential to specifically target critical disease-mediating RNAs while reducing the risk of 
systemic toxicity. However, transdermal delivery of siRNA is challenging because of the 
dense, occluding structure of the dermis and the chemical characteristics of siRNA. To 
achieve cutaneous siRNA delivery for treatment of ACD and other skin diseases, a potent 
transdermal enhancer is needed. ACD is a type IV delayed hypersensitivity initiated by 
skin sensitization to an allergen. Understanding of the pathophysiology of ACD is 
derived primarily from elucidation of events underlying contact hypersensitivity (CHS), 
where skin inflammation is induced skin contact by haptens. TNFα and MyD88 are 
inflammatory cytokines, involved in CHS progression, that are potential CHS treatment 
targets. In this study, we develop and tested a novel topical delivery system for siRNAs 
targeting TNFα (siTNFα) and MyD88 siRNA (siMyD88). The topical delivery system 
resulted in in vivo mouse dermis cell gene silencing efficiency of 62% for siMyD88 and 
54% for siTNFα siRNA, while siRNAs applied without the transdermal enhancer are 
ineffective. Treatment with combined siMyD88 and siTNFα significantly attenuated CHS 
symptoms in mice, better than treatment with siMyD88 or siTNFα as single agents. 
Combined siMyD88 and siTNFα reduced inflammatory cell infiltration into skin and 
local accumulation of CD8+ and CD4+ T cells. In summary, we have developed a novel 
delivery system for effective delivery of siRNA into skin cells for relief of CHS 
symptoms in mice. This is the first demonstration of topical gene silencing of TNFα and 
MyD88 to treat allergic reactions, highlighting a potential clinical use of RNAi therapy 
for skin and allergic diseases.  
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2.2 Introduction 
Topical delivery of therapeutic drugs is a particularly attractive strategy to treat skin 
disorders [1]. It maximizes direct drug contact with target skin cells while minimizing 
systemic exposure [2] as a method to increase treatment potency and reduce off-target 
toxicity through high local (but low systemic) dosage, and to maximize ease of use [3]. 
However, cutaneous delivery of therapeutic agents is challenging due to tight packing of 
corneocytes within a dense hydrophobic cellular matrix, and the dense network of 
polysaccharides and fibrous proteins in the stratum corneum [4] all of which constitute a 
physical barrier to drug entry. Potent transdermal delivery enhancers are essential to 
facilitate drug uptake.  
Contact dermatitis is an eczematous skin reaction caused by direct and usually repeated 
exposure to harmful objects or chemicals. It is one of the most common skin diseases and 
may vary from slight hyperkeratosis and small fissures to extensive redness, swelling and 
scaling [5]. There are three types of contact dermatitis: allergic contact dermatitis (ACD), 
irritant contact dermatitis, and photo-contact dermatitis. ACD is the most prevalent form 
of immunotoxicity in humans, and is a Type IV delayed hypersensitivity reaction 
mediated by hapten-specific T cells that generate inflammatory signals and induces 
apoptosis in epidermal cells. Inflammation and apoptosis result in skin inflammatory 
infiltrate and adverse clinical symptoms [6]. There are two phases during this process: the 
the sensitization phase and the elicitation phase. The sensitization phase occurs after the 
first contact of the hapten and the skin. The elicitation phase is also known as challenge 
phase, which occurs when the haptens challenge the sensitized individuals [7]. Our 
understanding of ACD derives from experiments undertaken in an animal contact 
hypersensitivity (CHS) model. In this study we use 1-fluoro-2, 4-dinitrobenzene (DNFB)-
induced CHS (a well-established animal CHS disease model) to explore the efficacy of a 
novel siRNA topical delivery vehicle, and targeting of TNFα and MyD88, to treat ACD.  
RNAi is an endogenous mechanism in which double-stranded RNA knocks down the 
expression of homologous genes to induce gene silencing. Since it was first observed in 
late 1980s, it had been used as a powerful laboratory technique to explore gene function 
[8]. Recent research on animal disease models of cancer, viral infection, age-related 
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macular degeneration, and other pathological conditions has resulted in development of 
RNAi molecules for treatment of human diseases. However, the lack of specific and 
effective in vivo delivery methods is a major impediment to clinical application [9, 10].  
Tumor Necrosis Factor alpha (TNFα) is a systemic cytokine mediating inflammation. 
TNFα activates neutrophils, up-regulates endothelial adhesion molecules, increases 
capillary permeability, and exerts direct cellular toxic effects [11]. In the CHS model, 
release of TNFα can activate local endothelial cells and facilitate T cell recruitment [11, 
12].  
The Myeloid Differentiation primary response gene 88 (MyD88) is critical for signaling 
from all Toll-like receptors (TLRs) except TLR3 [13]. MyD88 is expressed in a variety 
of human and murine tissue albeit at varying levels [14]. It involves Toll/interleukin-1 
receptor (TIR) signaling pathway, which results in NF-кB activation, cytokine secretion 
and inflammatory response. Recently, Paul A. Klekotka’s study shows that MyD88 
deficient mice were unable to mount an CHS model response [15]. 
In this study, we describe a novel topical RNAi delivery therapy for CHS. We report that 
topical administration of siRNA encapsulated in the new delivery vehicle silences 
expression of MyD88 and TNFα in dermal cells and inhibits progression of CHS by 
reducing local accumulation of inflammatory CD4+ T cells and CD8+ T cells.  
 
2.3 Materials and Methods 
2.3.1 Chemicals 
1,2,3-Propanetriol (glycerol) and 1-fluoro-2,4-dinitribenzene (DNFB) were purchased 
from Sigma-Aldrich, Inc. (Oakville, Ontario, CA). Dimethyl sulfoxide (DMSO) was 
purchased from Caledon Laboratory Chemicals, Inc. (Georgetown, Ontario, CA) and 
lipofectamine 200 (L2K) was purchased from Invitrogen Life Technologies, Inc. 
(Burlington, Ontario, CA).Glycerol was purchased from VWR International, Inc. 
(Edmonton, Alberta, CA) 
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2.3.2 Mice 
BALB/c mice (male, 6-8 weeks old) were purchased from Jackson Laboratory (Bar 
Harbor, ME, USA) and maintained under pathogen-free conditions in the barrier facility 
at The University of Western Ontario. All experiments were performed in accordance 
with the Guide for the Care and Use on Animals Committee Guidelines and standard 
operating procedures as required by the Animal Use Subcommittee of The University of 
Western Ontario. 
 
2.3.3 siRNAs 
Double-stranded siRNAs targeting murine TNFα siRNA (siTNFα) and MyD88 siRNA 
(siMyD88), and control non-targeting scrambled siRNA (siScramble) were obtained from 
Dharmacon, Inc. (Lafayette, CO, USA). The sequences were: 
siTNFα:  sense, 5’-GACAACCAACUAGUGGUGC-3’ 
   antisense, 5’-GCACCACUAGUUGGUUGUC-3’ 
siMyD88:  sense, 5’-CAGCGAGCUAAUUGAGAAAUU-3’ 
   antisense, 5’-UUUCUCAAUUAGCUCGCUGUU-3’ 
siScramble:  sense, 5’-CGUACGCGGAAUACUUCGA-3’ 
   antisense, 5’-CGTACGCGGAATACTTCGA-3’  
 
2.3.4 In vitro silencing of TNFα and MyD88 
B16F10 cells were transfected with siTNFα and siMyD88 using L2K. Untreated cells and 
cells transfected with siScramble were used as controls. Briefly, cells were plated in 24-
well plates (1.5×105 cells per well) and allowed to grow for approximately 16 h (80% 
confluence), transfected with siTNFα (1 μg/well) and/or siMyD88 (1 μg/well) in 500 l 
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serum-free medium for 4 h, and then incubated in complete medium for 24 h. Cells were 
then harvested for RNA isolation.  
 
2.3.5 TNFα and MyD88 mRNA measurement 
After in vitro transfection with siTNFα or siMyD88, total tissue or cellular RNA was 
isolated using Trizol (Invitrogen, Burlington, Ontario, CA) and used as a template for 
cDNA synthesis and non-quantitative PCR and quantitative PCR (qPCR). qPCR 
reactions were performed as described previously [16] using gene-specific forward and 
reverse primers (100 nM each) and SYBR Green PCR Master mix (Stratagene, La Jolla, 
CA) in a Stratagene MX 4000 Multiplex qPCR System. Primers used for the 
amplification of murine TNFα, MyD88 and GAPDH (control to assess relative levels of 
TNFα and MyD88 mRNA) were: 
TNFα:  forward, 5’-CTCCCTCCAGAAAAGACACCAT-3’ 
   reverse, 5’-ATCACCCCGAAGTTCAGTAGACAG-3’ 
MyD88:  forward, 5’-TAGACCGTGAGGATATACTGAAGG-3’ 
   reverse, 5’-TTAGCTCGCTGGCAATG-3’ 
GAPDH: forward, 5’-TGATGACATCAAGAAGGTGGTGAA-3’ 
   reverse, 5’ -TGGGATGGAAATTGTGAGGGAGAT-3’  
 
2.3.6 Development of topical siRNA delivery reagent 
Fluorescently-labeled siRNAs with or without candidate topical transdermal delivery 
vehicle, and candidate transdermal delivery vehicles alone, were prepared as follows: 
  A: L2K (5 l+ 15 μl nuclease-free water (NFW)) 
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  B: Glycerol (5 l+15 l NFW) 
  C: L2K (1 l)+Cy3 siRNA (2 g/8 l NFW)+NFW (11 l) 
  D: Glycerol (5 l)+Cy3 siRNA (2 g/8 l NFW)+NFW (7 l) 
  E: L2K (1 l)+Glycerol (5 l)+Cy3 siRNA (2 g/8 l NFW)+NFW (6 l) 
  F: DMSO (5 l)+Cy3 siRNA (2 g/8 l NFW)+NFW (7 l) 
  G: L2K (1 l)+Glycerol (5 l)+DMSO (5 l)+NFW (9 l) 
  H: L2K (1 l)+DMSO (5 l)+Cy3 siRNA (2 g/8 l)+NFW (6 l) 
  I: Glycerol (5 l)+DMSO (5 l)+Cy3 siRNA (2 g/8 l)+NFW (2 l) 
  J: L2K (1 l)+Glycerol (5 l)+DMSO (5 l)+Cy3 siRNA(2 g/8 l)+NFW (1 l)  
Each was applied onto the shaved dorsal skin of CD1 mice in a 0.5 mm2 area. Mice were 
sacrificed and dorsal skin resected and fixed in OCT for cryosectioning. Fluorescent was 
observed microscopically to assess cell and tissue uptake of a model fluorescently-
labeled but non-targeting siRNA.  
 
2.3.7 Preparation and application of a topical delivery reagent for 
CHS 
Glycerol (8 l), DMSO (1 μl), L2K (1 l) and 8 μl NFW water Glycerol (8 l), DMSO (1 
μl), L2K (1 l) and 2 μg siTNFα diluted in 8 μl NFW water or Glycerol (8 l), DMSO (1 
μl), L2K (1 l) and 2 μg siMyD88 diluted in 8 μl NFW water or Glycerol (8 l), DMSO 
(1 μl), L2K (1 l), 1 μg siMyD88 and 1 μg siTNFα diluted in 8 μl NFW water were 
mixed and applied in mouse right ear in each treatment group. Reagents were applied 
from day1 and applied once/day for 4 days.  
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2.3.8 Assessment of siRNA stability in serum  
SiRNA (0.3 μg) was mixed with novel reagents and incubated in fetal bovine serum (FBS) 
20l (Gibco, Burlington, ON, CA) for 1, 2, 3, and 4 h. The mixture was collected at each 
time point and siRNA degradation was assessed by loss of intensity of bands visualized 
by gel electrophoresis.  
 
2.3.9 Mouse CHS model and siRNA administration 
DNFB (25 μl of a 0.5% solution in acetone/olive oil [4:1]) was applied to both right and 
left mouse ears on day 0 and day 1 (the second application was to the same area as the 
first) to generate CHS model conditions. DNFB (10 μl of 0.2% in 4:1 actone/olive oil) 
was applied to the same region on the right ear only on day 5 as an immunogenic re-
challenge (the immunogen application area on the left ear was re-challenged with vehicle 
only). SiRNAs in each candidate topical application vehicle was applied after the DNFB 
application (4 hours post DNFB application) on day 1. SiRNAs in each candidate topical 
application vehicle was applied to the immunogen application on the right ear only on 
days 1, 2, 3, and 4. Experimental groups were: 
1. Untreated control 
2. DNFB alone without siRNA treatment 
3. DNFB with topical delivery reagent alone 
4. DNFB with siTNFα (2 μg) in candidate topical delivery reagent 
5. DNFB with siMyD88 (2 μg) in candidate topical delivery reagent 
6. DNFB with both siTNFα (2 μg) and siMyD88 (2 μg) in candidate topical delivery 
reagent.  
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2.3.10 Assessment of the degree of DNFB-induced CHS  
Ear swelling: Mouse ear thickness was measured 48 h after the last DNFB hapten 
treatment. Net ear swelling was the thickness of the DNFB-treated ear (measured 48 h 
after the final DNFB treatment) minus the thickness of the vehicle-treated ear measured 
at the same time. 
Redness and scaling: Redness and scaling in each ear were subjectively assessed by 2 
independent observers on a scale of 1 to 9 (9 being the greatest amount of redness or 
scaling and 1 the least) daily from day 1 to 8. The first measurement was finished 24 h 
after the first DNFB application and before the second DNFB application. Each category 
has maximally three scores; therefore the highest score will be 9 in this scoring system. 
The scores for each of the three symptom categories (redness, swelling, and scaling) were 
added to provide an overall estimate of CHS symptom intensity. Differences between and 
among treatment and control groups were analyzed for significant differences indicative 
of the capacity of siRNAs targeting TNFα and/or MyD88 to alleviate CHS symptoms. 
 
2.3.11 Assessment of neutrophil infiltration into dermis  
24 h post challenge, skin from treated ear regions were dissected from mice, fixed in 10% 
formalin, embedded in paraffin, sectioned (5 μm) and Hematoxylin and eosin (H&E) 
stained, in which basophilic white blood cells stain dark blue and eosinophilic white 
blood cells stain bright red, neutrophils stain a neutral pink.  
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2.3.12 Immunohistochemical visualization of CD4+ CD8+ T cells in 
skin 
Skin tissue was fixed in OCT to obtain frozen sections. Sections were incubated with 
primary αCD4 and αCD8 MAbs (Abcam, Cambridge, USA, diluted 1:100), incubated 
with biotinylated secondary Ab (45 min), and then with horseradish peroxidase-labeled 
streptavidin (37◦C, 45 min). Slides were diaminobenzidene (DAB)-stained and 
counterstained with hematoxylin.  
 
2.3.13 Statistical analysis 
All data are presented as mean of n measurements ± SD. Statistical comparisons between 
groups were performed using Student’s t-test. Statistical significance was determined a 
priori to be achieved when p<0.05. 
 
2.4 Results 
2.4.1 Development of a new topical reagent for siRNA delivery 
Transdermal delivery was, at one time, sufficiently problematic that intact skin was 
considered to be completely impermeable to all substances [17]. The greatest barrier to 
transdermal delivery is the tight structure of the stratum corneum (SC) in epidermis. The 
SC is composed of both keratin-rich corneocyte and the hydrophobic lipid-rich matrix 
which serve as the “bricks” and “mortar” of SC [1]. To test the capacity of candidate 
delivery agents, we compared the ability of those agents to deliver siRNA into and 
through skin. Candidate reagents were mixed with Cy3-labelled siRNA and applied to a 
fixed area (0.5 cm2) of dorsal skin on live mice.  
L2K is a well-established and widely used reagent for gene transfection in vitro [7]. 
Glycerol is a common ingredient in many skin medicines [8]. Firstly, it has to be 
confirmed that L2K and glycerol alone did not display auto-fluorescence (Fig. 2-1A&B). 
L2K alone did not deliver siRNA through the stratum corneum and into dermis (Fig. 2-
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1C). Glycerol as a single agent delivered siRNA into dermis (Fig. 2-1D). A combination 
of glycerol and L2K increased the amount of siRNA delivered into dermis, and did so to 
a greater degree than glycerol or L2K alone (i.e., the degree of fluorescence due to the 
presence of Cy3-labeled siRNA was greater) (Fig. 2-1E). These data support the 
hypothesis that glycerol combined with L2K is the most effective facilitator of siRNA 
entry into dermis compared to either reagent alone.  
DMSO is a universal drug delivery reagent successfully used in many in vivo drug 
delivery systems [18, 19]. It is comfirmed that DMSO combine with L2K and glycerol 
has no auto-fluorescent (Fig1 2-1G). DMSO alone delivered Cy3-labeled siRNA into 
skin, to a degree similar to that observed with glycerol alone (Fig. 2-1F). However, the 
pattern of delivery suggested that delivery efficiency was uneven and irregular compared 
to glycerol (i.e., some dermis regions received high levels of siRNA while others 
received little). DMSO combined with L2K facilitated transfer of Cy3-labeled siRNA 
into dermis, although a large fraction of applied siRNA remained on the skin surface 
without penetrating deeply (Fig. 2-1H). A combination of DMSO and glycerol facilitated 
siRNA transfer into dermis better than other single transfer reagents or two reagent 
combinations (Fig. 2-1I). However, the most effective Cy3 siRNA transfer (i.e., 
fluorescent staining in dermis) was mediated by combining glycerol, DMSO, and L2K 
(Fig. 2-1J). These data support the hypothesis that a combination of glycerol, DMSO, and 
L2K is the most efficient combination of delivery agents among those tested for transfer 
of siRNA across the stratum corneum and into dermis.  
 
2.4.2 Optimization of glycerol:L2K:DMSO siRNA delivery reagent 
We further optimized the glycerol:L2K:DMSO topical siRNA delivery reagent 
combination by testing the relative capacity of different glycerol:DMSO ratios (v/v) to 
deliver Cy3-labeled siRNA to dorsal mouse skin dermis. Lower glycerol concentrations 
were relatively ineffective while increased glycerol with decreased DMSO enhanced  
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Figure 2-1 Development of a novel topical delivery adjuvant for siRNA. The indicated 
reagents (combinations A-J, as described in the text) were mixed and 20 l applied to 
mouse skin, as described in Materials and Methods. Mice were euthanized at 4 h post-
treatment and skin collected for bright field and fluorescent microscopy. Fluorescence 
indicates the presence of Cy3-labeled siRNA. 
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siRNA delivery. Considering that DMSO may cause skin irritation if absorbed through 
skin, and increased viscosity could facilitate penetration by prolonging residency of the 
mixture on the skin surface, we tested additional glycerol:DMSO ratios  and observed 
that ratios of 9:1 retained a high level of penetration without inducing skin rash. We 
concluded that the optimal combination for glycerol:DMSO:L2K:siRNA solution was 
9:1:1:8 in a volume ratio(Fig. 2-2). In this experiment, 2 g siRNA dissolved in 8 l 
NFW was used as siRNA solution. 
 
2.4.3 TNFα and MyD88 knockdown in vitro and in vivo 
To validate the efficacy of siRNAs selected to knock down MyD88 (siMyD88) and 
TNFα (siTNFα), we transfected mouse melanoma cells (B16) in vitro which each siRNA. 
MyD88 and TNFα mRNA levels were largely decreased 24 h post-transfection in B16 
cells (Fig. 2-3A). Thus, the siRNAs selected to reduce each of these mRNA targets are 
effective. 
To evaluate in vivo gene silencing after topical delivery of siMyD88 and siTNFα on mice 
dorsal skin, we prepared glycerol:DMSO:L2K:siRNA (9:1:1:8) and apply it topically to 
dorsal mouse skin. The mice were sacrificed 24 h after application and skin was collected 
for determination of target mRNA levels. MyD88 and TNFα mRNA were reduced by 
62% and 54% respectively (Fig. 2-3B, C). 
Another consideration is that siRNA might be easily degraded in the topical application. 
To clarify whether the reagent may facilitate protection of RNA degradation, we mixed 
siRNA prepared with topical reagent or without topical reagent with freshly-prepared 
mouse plasma (rich in RNases). Undegraded siRNA was visualized by electrophoretic 
mobility at various incubation times. Compared to naked siRNA, the topical delivery 
reagent successfully protected siRNA from degradation (Fig. 2-3D). 
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Figure 2-2 Optimization of topical siRNA delivery using a combined glycerol:DMSO 
cocktail. L2K (1 μl) and Cy3-labeled siRNA (8 μl) were mixed with glycerol and DMSO 
at the indicated volume ratios and applied to mouse skin as described in Materials and 
Methods. Mice were sacrificed 4 h post-treatment and skin was collected for bright field 
and fluorescent microscopy. Fluorescence indicates the presence of Cy3-labeled siRNA. 
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Figure 2-3 siRNA-mediated gene silencing of MyD88 and TNFα in vitro and in vivo. (A) 
In vitro silencing efficacy of siMyD88 and siTNFα siRNA: B16F10 cells were cultured 
and transfected with siRNAs targeting MyD88 and/or TNFα, or control, non-targeting 
siRNA (siScramble). MyD88 and TNFα mRNAs were measured relative to GAPDH 
mRNA at 24 h post-transfection by RT-PCR and gel electrophoresis as described in 
Materials and Methods. (B, C) In vivo silencing of MyD88 and TNFα in skin: siMyD88, 
siTNFα, or siScramble were mixed with the novel delivery reagent 
(glycerol:DMSO:L2K:siRNA = 9:1:1:8) and applied to mouse skin. Mice were 
euthanized and skin collected at 24 h post-treatment. The levels of MyD88 and TNFα 
mRNA were determined by qPCR as described in Materials and Methods. Relative 
quantity of MyD88 and TNFα mRNA was expressed as mean ± SD. *Student's t-test, 
p<0.05. (D) Delivery reagent protection of siRNA from serum-mediated degradation: The 
novel reagent and 0.3 g siRNA were mixed with 20μl FBS and incubated in 370C for 1, 
2, 3, or 4 h. Integrity of siRNA was detected by gel electrophoresis as described in 
Materials and Methods. 
 
 
 
 
 
 
 
 
 
 
84 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control     siScramble     siMyD88 Control     siScramble     siTNFα 
GAPDH 
MyD88 
GAPDH 
TNFα 
R
el
at
iv
e 
ex
pr
es
si
on
 o
f M
yD
88
 
R
el
at
iv
e 
ex
pr
es
si
on
 o
f T
N
Fα
 
0                1              2              3           4 
0                1              2              3           4 
Naked siRNA 
Reagent siRNA mixture 
A 
B
C
85 
 
2.4.4 Attenuation of CHS by topical treatment with siMyD88 and 
siTNFα in delivery reagent 
DNFB is commonly used to induce model contact dermatitis in mice [20, 21], 
characterized by swelling, redness and scaling [5]. We hypothesized that silencing of 
MyD88 and TNFα in local skin tissue would reduce both swelling [22] and the severity 
of other symptoms due to reduction in cell-mediated responses mediated by MyD88 and 
TNFα during CHS sensitization phase [15]. To this end we applied freshly-prepared 
topical delivery agent with siTNFα and/or siMyD88 daily to the skin of mice. After 4 d 
treatment with siMyD88 or siTNFα alone, or siMyD88 combined with siTNFα, the 
overall clinical symptoms of redness, swelling and scaling (as assessed by subjective 
inspection of skin sections) were decreased compared to CHS treated with topical 
delivery reagent alone or untreated CHS (Fig. 2-4A). 
Ear swelling was reduced in groups treated with either single siRNA, implying that 
siTNFα and siMyD88 alone have protective and/or ameliorative capacity. Silencing of 
TNFα to reduce swelling of CHS has been reported and our result is consistent with that 
report [22]. On the other hand, use of siMyD88 to reduce swelling is reported by us for 
the first time. However, redness and scaling were reduced to only a minor degree by 
treatment with either siRNA alone. Combined siTNFα and siMyD88 treatment reduced 
swelling 48 h after re-challenge, compared to treatment with siTNFα or siMyD88 alone 
(Fig 2-4B). 
To have an overall and real time assessment of symptom including swelling, redness and 
scaling in different groups from day1 to day 8, we created a scoring system to assess the 
severity of CHS and applied that system to quantitate siRNA-mediated CHS symptom 
changes (after transfer of siRNAs, alone or in combination, in the glycerol:L2K:DMSO 
topical delivery reagent). Score from day1 is assessed 24 h after first DNFB application 
and before first treatment. Quantitative assessment revealed that reagent alone exerts a 
capacity to reduce CHS symptoms, implying that topical delivery reagent was both non-
toxic and therapeutic. Both single siRNA treatments (siTNFα alone or siMyD88 alone) 
have significantly attenuated the symptoms 24 h after the re-challenge. However, siTNFα 
alone could also significantly release the overall symptom 48 h after the second  
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Figure 2-4 Attenuation of CHS by topical delivery of siMyD88 and siTNFα: (A) CHS 
symptom severity in experimental and control groups: CHS was induced with DNFB as 
described in Materials and Methods. CHS in mouse ears was treated by topical 
application of glycerol:DMSO:L2K:siRNA (9:1:1:8) alone (Reagent) or containing 
siMyD88 + siTNFα, siMyD88 alone, or siTNFα alone. Control mice were left untreated 
with DNFB and did not suffer from CHS (Naïve reagent). All reagent and siRNA 
treatments were once per day for 4 days. Severity of symptoms was assessed 48 h after 
re-challenge with DNFB on day 4. (B) Quantification of swelling during CHS: Ear 
thickness was measured 48 h after re-challenge with DNFB on day 4. Net swelling 
thickness = (thickness, hapten re-challenged ear, μm) - (thickness, vehicle-treated ear, 
μm). *Student's t-test, p<0.05. 
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application of DNFB. Therefore, single siTNFα treatment can reduce the symptoms both 
in sensitization phase and elicitation phase while single siMyD88 treatment only reduce 
symptoms in elicitation phase. Combining siTNFα and siMyD88 resulting in alleviation 
of CHS symptoms to a greater degree than single siRNA treatment groups. The 
combination significantly attenuated the symptoms since 48 h after the first DNFB 
application and last for over 72 h after re-challenge, which covers nearly the whole 
sensitization phase and elicitation phase. When compare to single siRNA treatment, the 
severity of symptoms in combination treatment group significantly less from 24 h post re-
challenge to 72 h post re-challenge. These data suggest that simultaneous suppression of 
both TNFα and MyD88 provides a therapeutic advantage in preventing development of 
CHS symptoms and/or reducing their severity, over reduction of either target alone and 
particularly after repeated exposure to hapten (Fig. 2-5C). 
The number of infiltrating neutrophils in tissues affected by CHS is closely related to the 
severity of symptoms [22]. The H&E staining for the part in each group that carries most 
severe symdrom is shown in (Fig. 2-5D). Neutrophils are among the most important 
initiators and effectors of CHS [9]. To determine whether treatment with siMyD88 and 
siTNFα can reduce neutrophil infiltration in CHS, we treated ears of mice with siRNA in 
topical delivery reagent and quantitatively scored CHS symptoms (Fig. 2-5C) and 
subjectively observed neutrophil infiltration (Fig. 2-5D) at 48 h after DNFB rechallenge. 
Treatment with topical delivery reagent alone reduced swelling slightly (Fig. 2-5C) but 
did not reduce neutrophil infiltration (Fig. 2-5D). Treatment with single siRNAs reduced 
neutrophil infiltration in CHS compared to untreated CHS or CHS treated with topical 
delivery reagent alone (Fig. 2-5D). Combined treatment with both siTNFα and siMyD88 
were subjectively more effective at reducing neutrophil infiltration than treatment with 
single siRNAs (Fig. 2-5D). These data reveal that neutrophil infiltration in CHS can be 
reduced or prevented by down-regulation of MyD88 and TNFα through topical delivery 
of siRNAs. Moreover, the epidermis thickness obviously increased and Eosinophils cell 
clusters can clearly be seen. While this change is lighter in single treatment group, the 
combination treatment is mostly similar to naïve group (Fig. 2-5D). 
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Figure 2-5 Attenuation of CHS by topical delivery of siMyD88 and siTNFα. (C) CHS 
symptom severity in control and treated skin: Summary scores of CHS symptoms 
(redness, swelling, scarring) were evaluated from day 1 to day 8 as described in Materials 
and Methods. The data presented are from one of three independent experiments (n=6 
mice/group). *Student's t-test, p<0.05. (D) Neutrophil infiltration: CHS was induced in 
mouse skin and treated with siTNFα and siMyD88 as described in (C). Mice were 
euthanized 48 h post-rechallenge and skin collected for microscopic analysis of 
neutrophil infiltration, as described in Materials and Methods. 
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2.4.5 Immune suppression by topical delivery of siMyD88 and 
siTNFα  
It is believed that CD4+ cells and CD8+ cytotoxic T cells are important factors in CHS 
[20, 21, 23]. They accumulate locally in regions in direct contact with hapten and play a 
major role in triggering CHS. To assess whether treatment with siRNAs targeting TNFα 
and/or MyD88 modulated accumulation of these cells in CHS, mouse ear tissue was 
obtained after induction of CHS and 48 h after hapten rechallenge, and CD8+ and CD4+ T 
cell accumulation assessed by immunostaining. Obvious accumulation of CD8+ and 
CD4+ T cells was observed in untreated CHS. Treatment with single siRNAs (either 
siTNFα for siMyD88) reduced CD8+ (Fig. 2-6A) and CD4+ (Fig. 2-6B) T infiltration, but 
incompletely. The combination treatment with both siRNAs almost completely prevented 
infiltration by CD8+ and CD4+ T cells (Fig. 2-6A,f; Fig. 2-6B,x). These data suggest that 
topical delivery of siMyD88 and siTNFα can prevent accumulation of CD4+ and CD8+ T 
cells that contribute to CHS severity.  
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Figure 2-6 Immune suppression by topical delivery siMyD88 and siTNFα. (A) CD8+ T 
cell accumulation: Mice were treated with DNFB to induce CHS and re-challenged 4 d 
later with DNFB. At 48 h after re-challenge, mice were euthanized and skin was collected 
and stained with antibodies to detect CD8+ T cells: (a) Non treatment naïve mice; (b) 
mice with CHS without any treatment; (c) mice with CHS treated with reagent alone; (d) 
mice with CHS treated with reagent with siTNFα alone; (e) mice with CHS treated with 
reagent and siMyD88 alone and (f) mice with CHS treated with reagent mixed with 
siMyD88+siTNFα show the CD8+ cells. (B) CD4+ T cell accumulation. Skin sections 
were made as decribed above, and stained with CD4+ cells: T (g) Non treatment mice; (h) 
mice with CHS without any treatment; (i) mice with CHS treated with reagent alone; (j) 
mice with CHS treated with reagent with siTNFα alone; (k) mice with CHS treated with 
reagent and siMyD88 alone; (l) mice with CHS treated with reagent mixed with 
siMyD88+siTNFα represent the CD4+ positive cells. Pictures were taken under the 
microscope in 100 time magnification. The data presented complied results from 3 
experiments.  
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2.5 Discussion 
Topical delivery of siRNA has important advantages: First, it could directly target the 
cells in the disease site. Second, there is minimum worry about the risk of systemic side 
effects. Third, it is easy for administration since it is noninvasive, painless and readily 
accessible nature.  
However, the resilient barrier of the epidermal layers of the skin, primarily the stratum 
corneum, prevents the diffusion of exogenous chemical agents, which makes skin graft a 
significant obstacle to dermal and transdermal drug delivery [24]. Also, siRNA itself is 
difficult to be absorbed by skin and it is not stable enough [25]. Moreover, siRNA is 
negative charge which makes it being repelled by the cell membrane (also negative 
charge), and its size is relatively large makes it difficult to penetrate the cell. Even the 
siRNA successfully enters into cells, it might also face challenges as endosomal escape 
[1]. Various physical and chemical methods have been applied in previous study for 
overcoming the skin barrier while limiting the damage to the skin. Several studies has 
report the intradermal injection of DNA or siRNA in mouse skin model [1, 26-29]. 
However, transdermal injection can only be applied in small area of the skin and it is 
actually not user friendly and painful if multiple injections are necessary. To reduce the 
pain, needless injector which could generate high pressure beam of injection for physical 
penetration [30], or low frequency sonophoresis have been applied for transdermal 
delivery [31]. However, needless injector carries the sample problem of intradermal 
injection as they only able to cover small area of the skin, which limits their application. 
The sonophoresis technic needs the carrier of special equipment which could be costly 
while compare to chemical transdermal methods. Other study reported chemicals as 
acetone to weaken the stratum corneum, thus to facility the drug delivery. However, it is 
potentially harmful to skin since it is difficult to control the intensity of the weaken 
process [32].  
In this study, we create a novel reagent which could not only efficiently carry siRNA 
penetrating the stratum corneum, but also could help siRNA transfecting the cells in skin 
and achieve silencing.  
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We optimize the ratio between the components of the novel reagent to minimize the 
irritation to skin while maximally keeping the ability of penetration (Fig2). Base on the 
thickness measurement data and the score of syndromes in various experimental groups, 
the reagent control has lighter syndromes when compare to non-treatment group, which 
implies our reagent has certain level of protection function while apply on CHS mouse 
skin. It is reasonable since our reagent contains majority of glycerol, which plays a role in 
skin as hydration, cutaneous elasticity and epidermal barrier repair. As a lubricant, it has 
been applied in lots of commercial available skin care products [33]. The majority of 
glycerol in the combination makes the novel reagent retains a certain level of viscosity, 
which prevents the fast evaporation of the delivery combination and provides longer time 
for penetration. And solvent viscosity results in friction against proteins in solution, and 
this should result in decreased motion, inhibiting catalysis in motile enzymes [34], which 
might contribute to the stability of the siRNA in skin. DMSO is an important polar 
aprotic solvent that dissolves both polar and nonpolar compounds and is miscible in a 
wide range of organic solvents as well as water. It has a distinctive property of 
penetrating the skin very readily. However, topically apply DMSO alone can arose skin 
irritation, which has been observed in our study. L2K is well established as a reagent for 
in vitro siRNA delivery. It can condense with siRNA and brings them into cells 
efficiently. The novel reagent adopts the advantages of each component and minimized 
their weaknesses, which makes itself a powerful reagent to deliver various siRNA into 
skin layers and against various kinds of dermatologic diseases. Since RNAi owns the 
characteristic of specifically knock down the target genes, our therapy also displays a 
potential application in treating diseases with strong drug resistant.  
The DNFB induced CHS mouse model has been extensively studied and termed a Type 
IV delayed hypersensitivity reaction involving a cell-mediated allergic response. CHS 
arises as a result of two essential stages: An induction phase, which primes and sensitizes 
the immune system for an allergic response, and an elicitation phase, in which this 
response is triggered. In induction phase, contact allergens are able to cross the stratum 
corneum of the skin then the haptens will associate with epidermal proteins forming 
hapten-protein conjugates. The conjugate formed is then recognized as a foreign body by 
the MHC class I- expressing langerhans cells (LCs) (or Dendritic cells) [21]. Then the 
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LCs will internalize the protein; transport it via the lymphatic system to the regional 
lymph nodes; and present the antigen to T-lymphocytes. In the lymph glands, the 
differentiated DCs present the allergenic epitope, associated with the allergen, to T 
lymphocytes. These T cells then divide and differentiate, clonally multiplying so that in 
the elicitation phase when the allergen is experienced again by the individual, these T 
cells will respond more quickly and more aggressively. It is showed that both CD4+ T-
helper 1 (Th1) and CD8+ cytotoxic T-cells (Tc1) cells are crucial effectors in the CHS 
response to DNFB [23]. The CD8+ effector T cells migrate to the challenged site and 
initiate the skin inflammation via Fas and/or perforin-mediated cytolytic function [20, 35, 
36]. CD4+ T lymphocytes secreting IL-2 and IFN-γ play a preeminent role in the 
evolution of CHS. In this study, we treat mice after induction phase and before the 
elicitation phase. Our result agrees with these reports: compare to control group, there are 
less CD4+ CD8+ T cell accumulation in siTNFα and siMyD88 treatment group 48 h post 
challenge in the place where the reaction was triggered.  
TNFα is a very important mediator, which activates local endothelia to facilitate T cell 
recruitment[37, 38]. TNFα can also activate NF-kappa B which leads to the production 
and secretion of more inflammatory cytokines (IL-1, IL-6). Some study reported that 
TNFα level correlates with swelling, which is the classical manifestation of contact 
hypersensitivity. TNFα also closely related to the density of dermal infiltration [39]. 
Contact hypersensitivity initiates with innate immune reaction and results in an adaptive 
immune response. Toll like receptors constructs a vital important signal pathway for cells 
of innate immune system. MyD88 is the adaptor protein for all TLR members except 
TLR3. MyD88 associates with the Toll/interleukin-1 receptor (TIR) domain of TLRs, the 
interleukin-1 receptor-associated kinases IRAK1 and IRAK4, and tumor necrosis factor 
receptor-associated factor 6 (TRAF6) [40]. This interaction results in NF-кB activation, 
cytokine secretion and inflammatory response. Recently study report that IL-1R and IL-
18R/MyD88 pathways are required in distinctly different cells during the sensitization 
phase of CHS [41].  
97 
 
In current view, human ACD is a disease that once established, and then it lasts a lifelong. 
The only available etiologic treatment of ACD is elimination of the contact allergen [6]. 
Locally application of corticosteroids that targets lymphocyte activation remains the main 
approaches for ACD. However, corticosteroids has lots of side effects, such as cutaneous 
addiction, hyperglycemia, insulin resistance, diabetes mellitus, osteoporosis, cataract, 
anxiety, depression, colitis, hypertension, ictus, erectile dysfunction, hypogonadism, 
hypothyroidism, amenorrhoea, and retinopathy [42]. Our study provides a possibility of a 
new therapy for ACD, which is protective, potent and user-friendly.  
In conclusion, we report here a novel reagent that composed of glycerol, DMSO and L2K 
can effectively delivery siRNA into deep skin layer and achieve gene silencing, which 
leads to the syndrome attenuation of DNFB induced contact hypersensitivity, reduced 
inflammation cells infiltration and CD4+ CD8+ accumulation.  
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Chapter 3  
3 Targeted siRNA silencing of IDO in dendritic cells 
using mannose-conjugated liposomes: a novel 
strategy for treatment of melanoma 
3.1 Summary 
Indoleamine 2, 3-dioxygenase (IDO) expressed in antigen presenting cells (DCs) blocks 
T cell activation, induces T cell apoptosis, and promotes T cell differentiation into 
regulatory T cells (Tregs) that help tumor cells escape immune surveillance. Mannose 
receptors are highly expressed in antigen-presenting cells (APCs). In this study, we 
developed a novel APC-targeted siRNA delivery system using mannosed liposomes 
(Man-lipo) with encapsulated IDO siRNA (Man-lipo-siIDO), which preferentially knocks 
down IDO in melanoma bearing mice draining lymphnode and spleen. Mice treated with 
Man-lipo-siIDO had a delayed time of onset of implanted murine melanomas, increased 
survival time, reduced tumor size, and increased reactivity of T cells from spleen and 
lymph nodes against melanoma antigens. The enhanced anti-tumor immunity may be 
causally associated with inhibition of apoptosis in CD8+ and CD4+ T cells as well as Treg 
cells in spleen and lymph nodes. This study is the first to demonstrate that Man-lipo-
siIDO can preferentially target DCs and efficiently silence IDO expression in vitro and in 
vivo, events expected to enhance anti-tumor immune reactions against melanoma 
xenografts. This study supports the hypothesis that Man-lipo-siIDO may have potential 
for development as an immune-targeting therapeutic anticancer agent. 
 
3.2 Introduction 
Immune evasion and T cell tolerance induction have an important role in neoplastic 
growth, and recently, increasing evidence has demonstrated that tryptophan catabolism 
has a part in immune evasion. Indoleamine 2, 3-dioxygenase (IDO) is the first and rate 
limited enzyme that degrades tryptophan alone in kynurenine metabolic pathways. IDO 
plays an important role in immuno-regulation during infection, pregnancy, induction of 
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autoimmune events, transplantation, and neoplasia [1-3]. By depleting tryptophan, IDO 
induces cell cycle arrest in T lymphocytes and makes these cells more vulnerable to 
apoptosis, which subsequently leads to the attenuation of the immune system [1, 4, 5]. In 
addition, metabolic products generated by IDO, including kynurenine, 3-
hydroxykynurenine, 3-hydroxyanthranilic acid, and quinolinic acid, can cause cell cycle 
arrest and apoptosis [6]. Moreover, IDO can also induce differentiation of naive CD4+ T 
cells into regulatory T cells (Tregs) that further suppress anti-tumor immune responses [7, 
8]. A recent clinical study reported strong expression of IDO in malignant melanoma 
metastases that correlated with a high density of Foxp3-positive Treg cells and was 
associated with decreased survival times [9].  
RNAi is an endogenous mechanism in which double-stranded RNA specifically knocks 
down the expression of target genes to induce partial or complete gene silencing. Small 
interfering RNA (siRNA), a mediator of RNAi, has been used as a powerful laboratory 
tool to reduce or ablate gene expression [10]. Recently, investigation of RNAi 
applications in animal models of human diseases including cancer, viral infection, and 
age-related macular degeneration has moved RNAi forward into clinical applications. 
However, the lack of specific and effective in vivo delivery methods reduces the potential 
effectiveness of siRNA-based therapies [11, 12].  
Mannose receptors are highly expressed in cells of the immune system, especially in 
professional APCs including DCs and macrophages [13-15]. Transmembrane mannose 
receptors mediate endocytosis, function as antigen capture receptors, and are involved in 
antigen presentation [16, 17]. The preferential expression of mannose receptors in cells of 
the immune system makes them promising targets for various therapies, including 
macrophage-targeted chemotherapy and DC-targeted vaccines [18]. Mannose has been 
successfully applied to gene delivery to APCs and development of therapeutic vaccines, 
and some of them are currently undergoing clinical trials [19].  
In this study, we constructed mannosed liposomes (Man-lipo), as APC-targeted carriers 
for IDO siRNA (siIDO) delivery. We show that Man-lipo-siIDO can efficiently and 
preferentially silence IDO expression in DCs in vitro and in vivo; and that treatment with 
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Man-lipo-siIDO inhibited formation of melanoma tumour xenografts in recipient mice, 
restrained melanoma tumor xenograft growth, and enhanced anti-tumor immunity in 
xenograft host mice.  
 
3.3 Materials and Methods 
 
3.3.1 Chemicals  
1,3-Dioleoyl-3-trimethylammonium propane (DOTAP), cholesterol, 1,2-distearoyl-sn- 
glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (DSPE-
PEG2000- carboxylic acid) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy (polyethylene glycol)-2000] (DSPE-PEG2000) were purchased from Avanti 
Lipids, Inc. (Alabaster, AL). D-(+)-mannose and protamine sulfate were purchased from 
Sigma-Aldrich Canada, Ltd. (Ontario，Canada). All other chemicals were reagent grade.  
 
3.3.2 Mice 
C57BL/6 mice (6-8 weeks old males) were purchased from The Jackson Laboratory (Bar 
Harbor, ME) and maintained under pathogen-free conditions in the Western University 
barrier rodent facility. All experiments were performed in accordance with guidelines and 
standard operating procedures set out by the Canadian Council on Animal Care and the 
Western University Animal Use Subcommittee. 
 
3.3.3 IDO siRNA design  
A 21 nt, double-stranded siRNA targeting murine IDO, as described in our previous 
report [20] and synthesized by Dharmacon, Inc. (Lafayette, CO, USA). The sequences 
were: IDO sequence: sense, 5’-GGGCUUCUUCCUCGUCUCUTT-3’; antisense, 5’-
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AGAGAC GAGGAAGAAGCCCTT-3’. The sequence for scrambled siRNA was: sense, 
5’-CGUACGCGGAAUACUUCGA-3’; antisense, 5’-CGTACGCGGAATACTTCGA-3’.  
 
3.3.4 Cell culture  
Bone marrow-derived DCs were generated as previously described [21]. Briefly, bone 
marrow cells were flushed from the femurs, washed in ice-cold PBS, and cultured in 12-
well tissue culture plates (Corning, MA, USA; 2 X 106 seeded cells/well). Each well 
contained 2 ml of RPMI1640 medium (Invitrogen Life Technologies, CA, USA) 
supplemented with 10% FBS (Invitrogen Life Technologies) and penicillin (100 U/ml), 
streptomycin (100 μg/ml), 2-ME (50 μM; Invitrogen Life Technologies), recombinant 
murine GM-CSF (10 ng/ml; PeproTech, Quebec, Canada), and IL-4 (10 ng/ml; 
PeproTech). Non-adherent cells were removed after 48 h of culture, and medium was 
changed after every 48 h of culture. DCs were used for in vitro experiments after 7 days. 
B16-F10 mouse melanoma tumor cells were purchased from the American Type Culture 
Collection (ATCC, VA, USA) and grown and maintained in RPMI1640 tissue culture 
medium supplemented with 10% FBS. 
B16F10 murine melanoma cells were cultured in 75-mm culture dishes in Gibco’s 
minimal essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS; 
Burlington, ON, CA) and antibiotics (100 U/ml of penicillin and 100 lg/ml of 
streptomycin).  
3.3.5 Synthesis of DSPE-PEG2000-mannose lipid 
DSPE-PEG2000-amine (0.12 mmol) was lyophilized, dissolved in DMSO (2 mL), and 
mixed with mannose (1 mg) at 25o C for 16 h. The reaction mixture was then evaporated 
in a vacuum and the resulting dried material resuspended in water. The water suspension 
was dialyzed against distilled water for 48 h using a 3 kDa cut-off membrane (Spectrum, 
TX, USA). After the dialysis, the water suspension of DSPE-PEG2000-mannose was filter-
centrifuged using Amicon Ultra-15 centrifugal filter units with a 3 kDa MW cut-off 
(Millipore, MA, USA). The resulting suspension was lyophilized. 
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3.3.6 Preparation of Man-lipo-siIDO  
DOTAP, DPPC, cholesterols, and mannose-DSPE-PEG were mixed (3:10:10:4 molar 
ratio) to construct a mannose receptor-targeting liposome. The same reagents without the 
addition of mannose were used to construct the control, non-mannosed liposome. The 
lipids were dissolved in chloroform in a glass tube and evaporated to complete dryness 
under vacuum. The lipid film was hydrated by siRNA and protamine mixture. siRNA 
(targeting IDO in distilled water was added to an equal volume of liposomes and 
protamine at a ratio of 600 nmol DOTAP:30 μg protamine:50 μg siRNA and incubated at 
room temperature for 10 min to form multilamellar liposomes and siRNA mixture. The 
multilamellar liposome and siRNA mixture suspension was vortexed for 5 min followed 
by sonication for 2 min at 50°C in a bath sonicator, and the sonicated suspension was 
extruded sequentially through polycarbonate membranes of decreasing pore size (0.4, 0.2 
and 0.1 mm diameter pores). Finally, a post-insert technique [22] was used to construct 
non-mannosed and mannosed liposomes. The liposome nanoparticle solution was 
incubated (50°C, 10 min; followed by cooling to 25oC) with DSPE-PEG2000 or 
mannose-DSPE-PEG2000 to generate non-mannosed and mannosed liposomes, 
respectively. 
 
3.3.7 Mannosed liposome particle diameter and zeta potential 
Freshly prepared non-mannosed and mannosed liposomes were diluted with phosphate-
buffered saline (PBS) and the mean particle diameter and surface charge (zeta potential) 
measured using a Zetasizer Nano Series (Malvern Instruments Ltd., UK) according to the 
manufacturer's protocol. 
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3.3.8 In vitro uptake of liposomes loaded with Cy3 siRNA (Man-
lipo-Cy3 siRNA)  
Mouse dendritic cells were cultured for 6 days and then transfected with Man-lipo-Cy3 
siRNA, non-mannosed-lipo-Cy3 siRNA, empty Man-lipo, empty non-mannosed-lipo, or 
naked Cy3 siRNA. Cells were harvested 4 h after transfection and Cy3 fluoresence 
visualized by fluorescent microscopy. Untransfected DCs and DCs transfected with Man-
lipo-Cy3 siRNA or non-mannosed-lipo-Cy3 siRNA were similarly collected 4 h post-
transfection and analyzed for Cy3 siRNA uptake by flow cytometry. 
 
3.3.9 In vitro silencing of IDO in DCs using Man-lipo-siIDO 
Mouse DCs were cultured for 6 days and then transfected with Man-lipo-siIDO. 
Mannosed liposomes loaded with control siRNA (non-complementary to any known 
mouse RNA; Man-lipo-siScramble) were used as negative controls. Total cellular RNA 
was isolated from DCs 24 h after transfection for quantitative PCR analysis. 
 
3.3.10 In vivo distribution of Man-lipo-Cy3-siRNA 
Non-mannosed-lipo-Cy3 siRNA or Man-lipo-Cy3 siRNA were injected intravenously 
into mouse tail veins (50 μg/mouse). Mice were euthanized 6 h post-injection and organs 
(heart, liver, spleen, lung and kidney) collected, rinsed with saline, snap-frozen in liquid 
nitrogen, mounted for cryostat sectioning, and viewed using fluorescent microscopy.  
 
3.3.11 In vivo silencing of IDO using Man-lipo-siIDO 
Man-lipo-siIDO and Man-lipo-siScramble were injected intravenously into mouse tail 
veins (50 μg/mouse). Mice were euthanized 24 h later and splenocytes and lymphocytes 
were collected for RNA isolation. All RNAs were prepared for quantitative PCR analysis. 
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Man-lipo-siIDO and Man-lipo-siScramble were injected intravenously into mouse tail 
veins (50 μg/mouse). Mice were euthanized 24 h later and splenocytes and lymphocytes 
were collected and CD11C+ DCs were isolated using CD11C mouse Microbeads 
(Miltenyi Biotec, Auburn, CA) for RNA isolation. All RNAs were prepared for 
quantitative PCR analysis. 
3.3.12 Quantitative PCR analysis of IDO mRNA 
After in vivo treatment of mice or in vitro treatment of DCs with liposomes loaded with 
control or IDO siRNA, total cellular or tissue RNA was isolated using Trizol (Invitrogen) 
and then used as a template for cDNA synthesis and quantitative PCR (qPCR). qPCR 
reactions were carried out using gene-specific forward and reverse primers (100 nM each) 
and SYBR Green PCR Master mix (Stratagene, La Jolla, CA,) in a Stratagene MX 4000 
Multiplex qPCR System. Primers used for the amplification of murine IDO and GAPDH 
were: IDO, 5’-GAAGGATCCTTGAAGACCAC-3’ (forward) and 5’-
GAAGCTGCGATTTCCACCAA-3’(reverse); GAPDH, 5’-
TGATGACATCAAGAAGGTGGTGAA-3’ (forward) and 5’ -
TGGGATGGAAATTGTGAGGGAGAT-3’ (reverse). 
 
3.3.13 Effect of Man-lipo-siIDO on in vivo mouse melanoma tumor 
growth 
B16-F10 mouse melanoma cells (2 x 105 cells) were suspended in 20 μl of PBS and 
injected s.c. and dorsally into each C57BL/6 mouse. Man-lipo-siIDO or control 
liposomes encapsulating 100ug siRNA in a volume of 300ul were injected i.v. into mice 
2 days prior to injection with tumor cells and once per week thereafter. Control mice 
were identically injected with tumor cells followed, at the same time as injection of mice 
with Man-lipo-siIDO, injection with vehicle control, Man-lipo-siScrambled, or non-
mannosed-lipo-siIDO. Mice were checked for tumor formation on alternate days. The 
day of tumor appearance was noted and thereafter each tumor was measured by caliper 
and volumes estimated using the following formula: tumor volume = 0.5 x (width2) x 
(length). 
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3.3.14 Flow cytometry  
Estimation of Cy3 siRNA incorporation by freshly-isolated and cultured DCs was 
performed by flow cytometry (BD Biosciences, CA). All monoclonal antibodies (mAbs) 
were from BD Pharmingen, NJ). T cell subsets were analyzed by staining with PE-
conjugated or Cy5-conjugated CD4 mAbs, Cy5-conjugated CD8 or CD25 mAbs, and 
FITC-conjugated FoxP3 antibodies. Apoptosis of T cells was determined by staining with 
the above mAbs, FITC-conjugated annexinV and Propidium iodide (PI). All flow 
cytometric analyses were performed using appropriate isotype controls. 
3.3.15 Tumor antigen response  
Mice were euthanized 28 days after tumor inoculation, T cell suspensions prepared from 
spleens and lymph nodes [23]. Spleenocytes from melanoma bearing mice were isolated 
by gradient centrifugation over Ficoll-Paque (Amersham Pharmacia Biotech, Montreal, 
Quebec, Canada) and cultured in 96-well plates (4x105 seeded cells/well) in the presence 
or absence of B16-F10 tumor Ag in a gradient concentration of 5ug/ml, 25 μg/ml and 50 
μg/ml for 72h. Tumor antigens were prepared as previous description [24]. Briefly, B16-
F10 cells were trypsinized and resuspended at a density of 5x106/ml in serium frees 
RPMI. Then the suspension was freeze-thawed by -80oC and 4°C cycles for at least 5 
times. The protein (from both cell cytoplasma and cell membrane) concentration of the 
lysate was determined by a commercial assay (Bio-Rad, Munich, Germany).The mixed 
lymphocytes and Ag were cultured at 37°C for 72 h in 200 μl of RPMI 1640 
supplemented with 10% FBS, 100 U/ml of penicillin, and 100 μg/ml of streptomycin and 
pulsed with 1 μCi/well of 3H-labelled thymidine (Amersham Pharmacia Biotech) for the 
last 18 h of culture. Results were expressed as mean counts per minute of triplicate 
cultures ± SEM. 
3.3.16 Statistical analysis 
Data are presented as means ± SD. Control and experimental data were compared using 
one-way ANOVA followed by Newman-Keuls testing. p-values less than 0.05 were 
assumed a priori to indicate significant differences. 
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3.4 Results 
 
3.4.1 Preparation and characterization of Man-lipo-siRNA 
The size and surface charge of liposomes are of vital importance to transfection 
efficiency and biodistribution [25]. Small size avoids preferential uptake by Kupffer and 
other reticuloendothelial cells, and a slight positive charge facilitates association with 
negatively-charged RNA and target cell plasma membrane components [26, 27]. To 
estimate whether Man-lipo-siRNAs prepared by us had the appropriate size and surface 
charge for effective in vivo delivery, we measured final liposomal particle diameter and 
zeta potential (Fig. 3-1, A and B). Particle size was approximately 180 nm (Fig.3-1A) and 
surface charge of Man-lipo-siRNA (represented by zeta potential) was slightly positive 
and approximately 20 mV (Fig. 3-1B). The Man-lipo and the Non-man-lipo has a similar 
size and zeta potential. The addition of mannose does not influence the size and zeta 
potential of the liposome. These data suggest that, according to previously described 
parameters, the size and surface charge of the prepared liposomes were suitable for 
potential in vivo siRNA delivery [28]. This experiment was repeated three times. In each 
experiment, over 300 liposome particles were tested.  
To determine whether IDO siRNA was encapsulated inside the liposome and protected 
from RNase degradation, the stability of liposomal siRNA was assessed. Fresh mouse 
plasma was mixed with Man-lipo-siIDO, non-mannosed-lipo-siIDO, or naked siIDO. 
Compared to naked siIDO, siIDO encapsulated within mannosed liposomes or non-
mannosed-liposomes were protected for at least 48 h (Fig. 3-1C) suggesting that 
liposomes provide protection against systemic degradation of siRNA by nucleophiles and 
nucleolytic enzymes, and that addition of mannose to liposomes does not diminish that 
protective capacity. 
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Figure 3-1 Preparation and characterization of Man-lipo-siRNA. (A & B) Determination 
of the size and zeta potential of Man-lipo-siRNA and non-mannosed-lipo-siRNA. Man-
lipo-siRNA or non-mannosed-lipo-siRNA were prepare as described in materials and 
methods. The size (A) and the zeta potencial (B) of Man-lipo-siRNA and non-mannosed-
lipo-siRNA were measured by zetasizer. (C) Serum protection assay. Naked siRNA, 
Man-lipo-siRNA, or non-mannosed-lipo-siRNA were incubated with fresh mouse plasma 
at 37 oC at various time points. 1, 4, 8, 24 and 48 h post incubation, liposomes that 
encapsulated siRNA were lysised by Tris-Triton 100. siRNA was visualized by agarose 
electrophoresis. The data shows the compiled data from all three experiments. 
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Non-mannosed-lipo-siRNA
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Non-mannosed-lipo-siRNA 178 7.071068
Man-lipo-siRNA 183 9.291573
Average Zeta potential  (mV) ±SD
Non-mannosed-lipo-siRNA 23.375 0.953502
Man-lipo-siRNA 21.95                                     0.43589
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3.4.2 In vitro targeting by Man-lipo-Cy3 siRNA and gene silencing 
of IDO  
DCs express mannose receptors [16] and are among the most important antigen-
presenting cells in vivo. To evaluate the targeting efficiency of Man-lipo-Cy3 siRNA to 
mannose receptor, DCs isolated from mouse bone marrow and cultured in vitro for 6 days 
were used to assess capacity of Man-lipo-Cy3 siRNA to deliver siIDO and reduce IDO 
mRNA levels. Compared to non-mannosed-lipo-Cy3 siRNA, Man-lipo-Cy3 siRNA has a 
significantly higher targeting efficiency and cellular uptake (Fig. 3-2, A and B).  
To determine the silencing efficiency of the Man-lipo-siIDO in vitro, Man-lipo-siIDO 
was used to deliver IDO siRNA to identically-prepared DCs in vitro. Compared to Man-
lipo-siScrambled, Man-lipo-siIDO significantly reduced the level of IDO mRNA (Fig. 3-
2C). The differences of IDO expression between the Non treatment control and Man-
lipo-siScrambled are not significant. This data demonstrates that Man-lipo-siIDO is 
capable of delivering siRNA to DCs and to reduce IDO expression. 
 
3.4.3 Bio-distribution of Man-lipo-Cy3-siRNA and in vivo IDO gene 
silencing 
To test targeting efficacy of Man-lipo-siRNA in vivo, we investigated the biodistribution 
of Man-lipo-Cy3 siRNA in mice. Man-lipo-Cy3 siRNA or non-mannosed-lipo-Cy3 
siRNA was injected into mice and the distribution of Cy3 siRNA (red fluorescent signal) 
to heart, liver, spleen, lung and kidney were compared between the two and with organs 
from mice untreated with liposomes (Fig. 3-3A). Compared to non-mannosed-lipo-Cy3 
siRNA controls or non-treatment controls, Man-lipo-Cy3 siRNA accumulated to a 
significantly higher in lymph node, spleen and liver, consistent with the reported location 
of mannose receptors in normal, non-tumor mouse tissue [19]. The fluorescence that 
represents the distribution of Man-lipo-Cy3 siRNA is consistant over 24 h and 48 h (data 
not shown), but the intensity of fluorescence is weaker as time goes by. Therefore, 6 h 
bio-distribution was chosen. This data indicates that Man-lipo-siRNA can preferentially 
target mannose  
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Figure 3-2 In vitro targeting assay of Man-lipo-Cy3-siRNA and gene silencing of IDO. 
(A) Transfecting DCs with Man-lipo-Cy3-siRNA. Six-day-cultured DCs were transfected 
with Man-lipo-Cy3-siRNA (k, l) and non-mannosed-lipo-Cy3-siRNA (i,j). Non treatment 
DCs (a,b), DCs treated with empty Man-lipo (c,d) or empty non-mannosed-lipo (e,f) and 
DCs treated with naked Cy3 labeled siRNA (g,h) served as controls. The red fluorescence 
of Cy3 was detected by fluorescent microscope 4h post transfection. The magnification is 
10x. (B) Transfection efficacy of Man-lipo-Cy3-siRNA detected by flow cytometry. Six-
day-cultured DCs were transfected by Man-lipo-Cy3-siRNA and non-mannosed-lipo-
Cy3-siRNA. 4 h after transfection, the cells were harvested and the fluorescence of 
encapsulated Cy3-labeled siRNA was detected by flow cytometry. Experiment were 
repeated three times. (C) Gene silencing of IDO using Man-lipo-siIDO. Six-day-cultured 
DCs were transfected by Man-lipo-siIDO and non-mannosed-lipo-siIDO. 24 h after 
transfection, DCs were harvested and message RNA was isolated. The IDO expression of 
DCs was detected by real time PCR. *p<0.05. 
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Figure 3-3 Bio-distribution of Man-lipo-Cy3-siRNA. (A) Bio-distribution of Man-lipo-
siRNA. Mice were i.v injected with Man-lipo-Cy3-siRNA and non-mannosed-lipo-Cy3-
siRNA. 6 h post administration, mice were sacrificed and lymph node, spleen, liver, heart, 
kidney, lung were extracted for frozen sections. The red fluorescence of Cy3-labeled 
siRNA in the various tissue sections was observed under fluorescent microscope. The 
data presented one of three independent experiments. The magnification is 10x.  
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receptor- expressing tissues and efficiently deliver siRNA into liver and important 
immune organs such as spleen and lymph node.  
In order to assess in vivo gene silencing efficacy in addition to siRNA delivery, Man-
lipo-siIDO was injected i.v. into mice. Expression of the IDO gene in lymph node and 
spleen was significantly reduced compared to organs in animals treated with Man-lipo-
siScrambled control (Fig. 3-4 A&B).  
To further confirm that DCs in vivo have been targeted and the IDO expression in DCs 
has been knocked down, 24 hours post administration, CD11C+ cells of non-treatment 
mice, mice injected with Man-lipo-siScramble and Man-lipo-siIDO were isolated from 
splenocytes and lymphocytes of Balb/C mice. Total RNA was isolated from the CD11C+ 
cells in different experiment groups and the IDO expression was determined by qPCR. 
The IDO expression in Man-lipo-siIDO treatment group was significantly decreased 
when compare to Man-lipo-siScramble, and no significantly different could be found 
between non treatment control and Man-lipo-siScramble treatment (Fig. 3-4 C).  
 
3.4.4 Therapeutic effects of Man-lipo-siIDO 
It has been reported that more aggressive tumor grow is observed in the cancer patients 
with more IDO+ DC expression in DCs [9]. In order to determine whether knock down of 
IDO may restrain the tumor growth, we treated melanoma-bearing mice with Man-lipo-
siIDO. As shown in Fig. 3-5 A&B&C, compare to non-mannosed-lipo-siIDO, Man-lipo-
siScrambled control and non-treatment control, melanoma bearing mice that were 
injected with Man-lipo-siIDO has lengthened time between tumor cell inoculation and 
the appearance of palpable tumors; reduced tumor size at equal times after tumor cell 
inoculation; lower tumor weight (28 days after tumor inoculation). The tumor weight is 
different between the Man-lipo-siIDO and non-mannosed-lipo-siIDO treatment groups 
when compared to tumor size. Compared to melanoma in early stage, advanced 
melanoma contains more liquid inside the tumor since advanced vascularization is 
formed. The early stage melanoma contains more connective tissue,  
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Figure 3-4 In vivo gene silencing of IDO. (A & B) In vivo gene silencing by Man-lipo-
siIDO. Man-lipo-siIDO or Man-lipo-siScrambled were i.v injected into melanoma 
bearing C57/BL6 mice. 24 h after injection, mice were sacrificed and the IDO expression 
in spleen (A) and lymph node (B) were detected by real time qPCR.*p<0.05. (C) In vivo 
silencing of IDO on CD11C+ DCs by Man-lipo-siIDO. Man-lipo-siIDO or Man-lipo-
siScrambled were i.v injected into C57/BL6 mice. 24 h after injection, mice were 
sacrificed and CD11C+ DCs were isolated for IDO expression determination. IDO 
expression was detected by qPCR. *p<0.05. The data presented complied results from 3 
experiments. 24 mice were randomly distributed in each group in each experiment.  
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Figure 3-5 Anti-tumor effects of Man-lipo-siIDO. (A & B) Experimental treatment of 
murine melanoma using Man-lipo-siIDO. Man-lipo-siIDO, or non-mannosed-lipo-siIDO, 
or Man-lipo-siScramble was i.v. injected into C57/BL6 mice two days before tumor 
inoculation. Treatments were repeated once a week thereafter. Tumor size (A) in 
treatment and control mice was monitored every three days. Onset time (B) in treatment 
and control mice was monitored every day after tumor inoculation. (C) Tumours in 
different experimental groups or control groups were extracted and weighted in day 28 
after mice were sacrificed. Results represent compiled data from all three experiments. 
Each point represents the weight of 6 mice in each group. Results represent 1 of 3 
experiments.*p<0.05 (Man-lipo-siIDO vs non-mannosed-lipo-siIDO) 
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which usually located between the malignant tissue and normal tissue, includes skin and 
muscle. Since the size measurement includes the connective tissue but the weight 
measurement does not include the connective tissue, which may explain the inconsistence 
between the tumor size and tumor weight measurement.  
Accumulation of IDO+ DC in lymph node correlates the poor prognosis of cancers by 
inducing CD4+ and CD8+ T cells apoptosis, which subsequently leads to the slowing of 
tumor growth [6, 9, 29]. In order to identify that silencing IDO expression in spleen and 
lymph node can reduce CD4+ and CD8+ T cell apoptosis, splencoytes and lymphocytes 
isolated by Ficoll were stained with Cy5-conjugated CD4 mAbs, Cy5-conjugated CD8, 
FITC-conjugated annexin V and PI were detected by flow cytometer. Dead cells were 
excluded by PI staining in analysis. Compare various control groups, the CD4+ and CD8+ 
apoptosis T cells population in drain lymph node, lymph node and spleen were 
significantly less in Man-lipo-siIDO injected mice (Fig. 3-6 A-F). When compared to 
Man-lipo-siScramble, non-mannosed-lipo-siIDO has significantly less apoptosis CD4+ 
cells in draining lymph node and spleen, also less apoptosis CD8+ T cells in non-draining 
lymph node and spleen. However, the apoptosis was further reduced by the addition of 
mannose into the delivery system. This suggests that Man-lipo-siIDO arouses anti-tumor 
effects might partially attribute to the reducing CD4+ and CD8+ T cell apoptosis 
population in spleen, lymph node and draining lymph node.  
 
3.4.5 Enhancement of anti-tumor immunity by Man-lipo-siIDO 
The expression of IDO induced tumor escape is mainly caused by the IDO induced T cell 
apoptosis and immune suppression[7]. Thus, we detected the anti-tumor immunity by 
evaluating the anti-tumor antigen ability of the splenocyte and lymphocyte. When 
compare to Man-lipo-siScramble and Non-treatment control, non-mannosed-lipo-siIDO 
treatment mice has relatively stronger reaction against to the B16-F10 melanoma antigen. 
The differences between Non-treatment control, Man-lipo-siScramble and non-
mannosed-lipo-siIDO are not statistically significant. Mice treated with Man-lipo-siIDO  
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Figure 3-6 Suppression of T cells apoptosis by Man-lipo-siIDO. C57/BL6 mice were 
treated with Man-lipo-siIDO, or non-mannosed-lipo-siIDO, or Man-lipo-siScramble, as 
described in the legend to Fig. 4. The mice were sacrificed in day 28, and the CD4+ and 
CD8+T cells in drain lymph node (A, B), lymph node (C, D) and spleen(E, F) were 
isolated. The apoptosis in CD4+ and CD8+ T cells were detected by flow cytometry after 
Annexin V staining. Results represent complied results from 3 experiments (n = 6 per 
group/experiment). *p<0.05. 
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have significantly stronger response against to tumor antigen when compared to mice 
treated with non-mannosed-lipo-siIDO (Fig. 3-7 A&B).   
Recent evidence suggests that IDO promotes the generation of induced Tregs[30]. 
Clinical studies reveal that there is a positive correlation between the levels of IDO 
induced Tregs and poor clinical outcomes [31]. We speculated that by down regulation of 
IDO expression, the expression of Tregs in spleen, especially in drain lymph node will be 
decreased. As shown in Fig.3-7 C&D, mice injected with Man-lipo-siIDO had lower 
Treg expression when compare to non-treatment control and Man-lipo-siScrambled 
control. These results highlight that the Man-lipo-siIDO was able to inhibit Treg cells and 
enhance the overall anti-tumor immunity of T cells. 
 
3.5 Discussion 
 
Increasingly accumulating data from clinical and basic research demonstrates that IDO 
plays an important role in tumor immune evasion[32]. The tumor escape induced by IDO 
is mostly attributed to IDO+ DC induced T cell apoptosis and Treg accumulation [9, 33, 
34], which leads to the immune dysfunction of the immune organ, especially the sentinel 
lymph node [35, 36]. However, effective therapy by knocking down the expression of 
IDO through specifically targeting APCs in lymph node and spleen has not yet been 
reported. In this study, we developed a APC-targeting delivery system based on specific 
affinity of mannosed-liposome to mannose receptor expressing APCs. We observed that 
Man-lipo-siIDO can efficiently target DCs and repress IDO expression on DCs in vitro 
and in vivo. By silencing IDO expression in spleen and lymph node of tumor bearing 
mice, tumor growth could be restricted, which might attribute to the significantly 
decreased of Treg cells populations as well as significantly decreased apoptotic CD4+ and 
CD8+ effector T cells in the draining lymph node and spleen.  
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Figure 3-7 Manipulation of anti-tumor immunity by Man-lipo-siIDO. (A & B) Tumor-
Ag-specific T cell response. T cells isolated from lymph node (A) and spleen (B) of 
various experimental and control groups were mixed with indicated concentration of 
tumor antigen respectively. Cells were pulsed with 1 μCi of [3H] thymidine for the last 18 
h. T cells proliferation level was determined by radioactivity detection. Results were 
expressed as the mean counts per min of triplicate cultures ± SEM (n = 6 per 
group/experiment) *= p<0.05 (Man-lipo-siIDO vs non-mannosed-lipo-siIDO). (C&D) 
Treg cells in Man-lipo-siIDO treated tumor-bearing mice. C57/BL6 mice were treated 
with Man-lipo-siIDO, or non-mannosed-lipo-siIDO, or Man-lipo-siScramble, as 
described in the legend to Fig. 4. After mice were sacrificed, CD4+ T cells from drain 
lymph node (C) and spleen (D) were isolated. CD4+CD25+FoxP3+ Treg cells were 
detected by flow cytometry. Results represent 1 of 3 experiments (n = 6 per 
group/experiment). *p<0.05. 
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RNAi is an endogenous mechanism in which double-stranded RNA knocks down the 
expression of homologous genes, thus induces gene silencing. Since it was first observed 
in late 1980, it had been used as a powerful laboratory technique for gene silencing [10]. 
Recently, some research on animal disease model, such as cancer, viral infection, and 
age-related macular degernation has moved RNAi forward in clinical application. 
However, the lack of specific and effective in vivo delivery methods is the major barrier 
for its application [11, 12]. While “flooding” the system with siRNA in the form of 
hydrodynamic administration is effective in animal models, this approach is not practical 
for clinical intervention [37]. The ability to selectively deliver siRNA to specific cells 
would allow for lower concentrations of siRNA to be used, as well as possibly the 
alleviating need for systemic delivery. We have been developed several tissue/cell-
specific targeting methods for siRNA delivery [38, 39] 
Comparing liposomes with other carrier delivery systems, liposomes offer multiple 
advantages for drug delivery, including their biocompatibility, biodegradability and 
safety. Mannosed liposomes have been considered as promising non-live vectors for 
targeted delivery purposes [40]. In order to achieve DCs-targeted delivery of IDO siRNA, 
we conjugated D-(+)-mannose to the liposome, which specifically binds to the Lectins 
expressed in mice/humans that have shown mannose-binding activity include 
transmembrane proteins such as the classical Macrophage mannose receptor (MMR 
group VI), Endo180, dendritic cell-specific intercellular adhesion molecule-3 grabbing 
non-integrin (DC-SIGN), DC-SIGN related (L-SIGN, group II, type 2 receptors) or their 
mouse homologues (SIGNR), Langerin or secreted/soluble proteins such as the collectins 
mannose binding protein (MBP), surfactant protein A and surfactant protein D (group III) 
[19].  
Mannosed particulates are formed by the association of the mannose derivative to a 
carrier (liposome, nanoparticle, etc.). The mannose derivative acts as a targeting agent 
whereas the particulate or carrier acts as a reservoir for the therapeutic agent. Because of 
their particulate nature, these particles will be engulfed by phagocytic APCs and 
mannosylation will further improve their phagocytosis mediated by specific receptors. 
Transmembrane mannose receptors mediate endocytosis, function as antigen capture 
131 
 
receptors and are involved in antigen capture and presentation[17, 41]. After recognition, 
MMR delivers the antigen to the early endosomes and recycles to the surface [42]. The 
content of endosomes is subsequently targeted to lysosomes in which the degradation 
produces antigen fragments that, after presentation in MHC molecules, can stimulate the 
adaptive immune responses[41]. For DC-SIGN, this receptor delivers the bound 
components to late endosomes or lysosomes where they are degraded. The generated 
antigens are processed for MHC class II presentation to T cells [43]. Under specific 
conditions, both MMR and DC-SIGN appear to deliver the antigens in MHC class I 
molecules [44, 45]. Mannosed liposome has been used in various vaccine studies 
targeting DCs in vivo. For example, the peptide-based mannosed lipoarabinomannan 
(ManLAM) is reported to be able to target the host DCs and arouse antibodies against 
Mycobacterium tuberculosis [46]. In our study, we observed a strong targeting ability of 
our Man-lipo-siRNA towards DCs. Further, We also observed that the Man-lipo-siIDO 
can efficiently target macrophage in vivo, which is also an important antigen presenting 
cell that influence T cell proliferation [5]. When compared to non-mannosed-lipo-siIDO, 
which could only deliver siRNA into 15% of CD11b+ cells in splenocytes and 
lymphocytes, the Man-lipo-siIDO could transfected up to 70% of CD11b+ cells in 
splenocytes and lymphocytes. The IDO expression can be significantly knocked down in 
macrophage (data not shown). In our study, although a much less targeting efficiency in 
Non-mannosed-lipo-siIDO groups when compared to Man-lipo-siIDO groups is observed, 
the restriction of tumor growth, reduction apoptotic CD4+ and CD8+ T cells and the up-
regulation of antigen response is significant. It could attribute to the characteristic of the 
liposomes; they would finally be engulfed by APCs when circulate in the circulation 
system. By being engulfed by the APCs, they silenced the IDO expression and exerted 
the anti-tumor effect. However, compared to non-mannosed-lipo-siRNA, the Man-lipo-
siRNA locates much more in spleen and lymph node and less located in liver. This result 
demonstrates that the addition of mannose to the liposome can enhance the cellular 
uptake of siRNA by guiding the whole lipoplex to organs that are rich of APCs and 
significantly increased the anti-tumor ability.  
DCs and macrophages are the most important APCs, which are closely related to cancer 
immunity and clinical outcome. Accumulating reports have extended on the immune-
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repressive role of IDO in cancer diseases [47]. IDO+ DCs in humans often show a 
morphology of plasmacytoid and express CD123 and CCR6 chemokine receptor 
simultaneously [48, 49]. It is possible that IDO expression of IDO in these cells was 
stimulated by Toll-like receptor (TLR)-9 ligands activation, and them facilitates the 
generation of adaptive Treg cells from naïve allogeneic CD4+CD25- T cells [7]. In mice, 
the IDO+ DCs occupies a proximally 0.3-0.5% of total lymph node cells, these cells 
accumulates in tumor-draining lymph nodes can results in local T cell repression[9]. In 
our study, we observed a significantly decreased apoptosis of CD4+ and CD8+ T cell in 
Man-lipo-siIDO groups, which demonstrates that by specifically silencing IDO, local T 
cell can be protected from apoptosis. We also successfully reduced the Treg population in 
both tumor draining lymph nodes and spleen, which plays an important role in limiting 
tumor growth and metastasis [50]. The splenocytes and lymphocytes are reinstalled with 
anti-tumor ability through our therapy, when compare to other controls, such as non-
mannosed-lipo-siIDO control, Man-lipo-siScrambled control and non-treatment control, 
Man-lipo-siIDO treated mice has significantly anti-tumor immunity, which further 
demonstrates that our therapy is preferentially targeting and potent.  
In summary, we report here a mannose expressing APCs targeting systems to delivery 
IDO siRNA can efficiently block the IDO expression in splenocytes and lymphocytes. 
Treatment of Man-lipo-siIDO results in significantly lengthened tumor onset time, 
reduced tumor size and tumor weight; decreased apoptosis of CD8+ and CD4+ T cells 
isolated from spleen and lymph nodes; increased reactivity of T cells isolated from spleen 
and lymphe nodes against B16 melanoma cell antigens and decreased 
CD4+CD25+FoxP3+ Treg cells isolated from spleen and draining lymph nodes. 
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Chapter 4  
4 Targeted siRNA silencing of BRAF in melanoma 
using folate receptor-conjugated liposomes 
4.1 Summary 
The high frequency of mutation (60-80%) in melanoma and its central role in regulation 
of cell proliferation and survival makes v-Raf murine sarcoma viral oncogene homolog 
B1 (BRAF) a heat key target for melanoma therapy. However, the off target and drug 
resistance effects create many difficulties in practical use. Targeting gene silencing by 
siRNA could be a promising alternative, since it is highly specific to the mRNA sequence 
of the intended gene. B16-F10 murine melanoma cell line retains high levels of BRAF 
expression while consistently expressing folate receptor. In this study, we constructed a 
liposomal folate receptors targeting siRNA delivery system. The B16-F10 targeting 
efficiency of folate liposome encapsulated siRNA (Folate-lipo-siRNA) was detected by 
flow cytometry in vitro and fluorescent microscopy in vivo. Cells that were transfected 
with BRAF siRNA had significantly less proliferation in vitro. In a mouse melanoma 
model, compared to controls (Non-treatment mice, mice treated with Folate-lipo-
siScramble, or with non-folate-lipo-siBRAF), mice treated with Folate-lipo-siBRAF had 
a reduced tumor volume, tumor weight and reduced expression of PCNA and vascular 
networks in tumor tissue. This study demonstrates that using Folate-lipo-siBRAF can 
preferentially silence BRAF expression in folate receptor expression cells in vitro and in 
vivo and that silencing BRAF by siRNA can prevent melanoma growth. This study 
highlights that Folate-lipo-siBRAF has potential for development as an anticancer 
therapeutic agent. 
 
4.2 Introduction 
Melanoma is the sixth most common cancer and the malignancy with the highest 
continuing rise in incidence [1]. For several decades the progress in the melanoma field is 
slow. Systemic therapies have made little or no contribution to overall survival rate [2-4]. 
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However, the identification of mutant BRAF, which is now known to be a major driver of 
melanoma progression, provided great progress in treatment of melanoma [5]. 
RAF is the first identified RAS downstream effectors. The RAF family is composed of 
three members, A-RAF, B-RAF and RAF1 (or C-RAF), within which, B-RAF is 
considerably stronger in kinase activity than the other two isotypes [6, 7]. B-RAF is 
serine threonine kinase, which is part of the RAF/MEK/ERK serine threonine kinase 
cascade. This cascade , also called ‘classical’ MAPK pathway, regulates cell growth, 
survival and differentiation [8].The discovery of oncogenic BRAF mutations in 
melanoma was in 2002, since then, B-RAF stands as one of the most powerful 
affirmations of the transformative potential of systemic cancer genome characterization 
[7, 9]. Recently, B-RAF mutations have been reported at high frequencies of over 70% in 
melanoma [10]. The mutations are also found in premalignant atypical or dysplastic nevi, 
which suggest that B-RAF activation could be an initiating event in tumorigenesis[11, 
12]. Lots of B-RAF inhibitors have emerged and been tested in clinical trials. However, 
resistance is found in the later or follow-up treatment on patients. siRNA therapy could 
be a potential alternative since siRNA can knock down the expression of any proteins or 
non-coding RNAs and can be easily synthesized or cloned into expression vectors 
(shRNA) with minimal toxicity. In contrast, chemical inhibitors against certain proteins 
are limited and constructing dominant negative mutants is time-consuming. Moreover, 
the chemical inhibitors and dominant negative mutants are more toxic to the cells 
compared with siRNAs [13].  
Folic acid is a water-soluble B vitamin, which is essential for de novo synthesis and one 
carbon transfer reactions[14].Folate receptors (FRs), also known as folate-binding 
proteins (FBP), are N -glycosylated proteins with high binding affinity to folate in vivo. 
FRs include at least four isoforms, α ,  ,  / γ ′and δ.The affinities of folic acid for the 
FRs are: FR- α , Kd~ 0.1 nM[15]; FR- β , Kd ~1 nM[16]; and FR- γ , Kd ~ 0.4 nM[17]. 
Functional FR expression is low or absent in most normal tissues, only FR- α expression 
in the luminal surface of certain epithelial cells [18], which are inaccessible to blood 
circulation. In contrast, many malignant cancers, especially epithelial carcinomas, 
consistently and uniformly express high levels of FR-, which is accessible to blood 
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circulation[14, 19].The frequent overexpression within tumors and highly restricted 
distribution in normal tissues suggest that both FR- and - can potentially be exploited 
as a tumor-specific cell surface marker that can be used in the targeted delivery of cancer 
therapeutics[14, 20]. Since B16-F10 melanoma over-express B-RAF while consistently 
expressing folate receptors [21], this makes it an ideal modal for investigating the 
potential therapeutic application of Folate-lipo-siBRAF. 
In this study, we constructed a liposomal folate receptors targeting siRNA delivery 
system which can preferentially knock down B-RAF in B16-F10 cells in vitro. 
Administration of folate receptor targeted liposomes encapsulated B-RAF siRNA 
(Folate-lipo-siBRAF) resulted in the knockdown of B-RAF expressing in tumor tissue, 
which leads to the reduced proliferation and vascularization of tumor cells in vivo.  
 
4.3 Materials and Methods 
 
4.3.1 Chemicals 
1, 3-Dioleoyl-3-trimethylammonium propane (DOTAP), cholesterol, folate-
distearoylphosphatidylethanolamine-N-poly(ethyleneglycol) (Folate-DSPE-PEG) and 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-
2000] (DSPE-PEG2000) were purchased from Avanti Lipids, Inc. (Alabaster, AL). All 
chemicals were reagent grade.  
 
4.3.2 Mice 
C57BL/6 mice (6-8 weeks old males) were purchased from The Jackson Laboratory (Bar 
Harbor, ME, USA) and maintained under pathogen-free conditions in the Western 
University barrier rodent facility. All experiments were performed in accord with 
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guidelines and standard operating procedures set out by the Canadian Council on Animal 
Care and the Western University Animal Use Subcommittee. 
 
4.3.3 BRAF siRNA design  
A double-stranded siRNA targeting murine B-RAF, as described in previous report[22] 
and was synthesized by Dharmacon, Inc. (Lafayette, CO, USA). The sequences were: B-
RAF sequence: sense, 5’-GCUUACUGGAGAGGAGUUACA-3’; antisense, 5’-
UGUAACUCCUCUCCAGUAAGC-3’. The sequence for scramble siRNA was: sence, 
5’-CGUACGCGGAAUACUUCGA-3’; antisense, 5’-CGTACGCGGAATACTTCGA-3’.  
 
4.3.4 Cell culture  
B16F10 murine melanoma cells were cultured in 75-mm culture dishes in Gibco’s 
minimal essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS; 
Burlington, ON, CA) and antibiotics (100 U/ml of penicillin and 100 lg/ml of 
streptomycin).  
 
4.3.5 In vitro silencing using siBRAF and evaluation of anti-
proliferation effect of siBRAF 
B16F10 cells were transfected with B-RAF siRNA using L2K (Invitrogen, Carlsbad, CA, 
USA). The non-treatment cells were used as negative controls. Briefly, cells were plated 
into 24-well plates (1.5×105 cells per well) and allowed to grow overnight, to reach 80% 
confluence. Cells were transfected with 0.5μgB-RAF siRNA in serum-reduced medium 
for 4 h, and then incubated in complete medium for 24 h. All RNAs were prepared for 
quantitative PCR (qPCR) analysis.  
24 h post siRNA transfection, B16-F10 cells were re-plated in 96 well/plate in a number 
of 500/well. Cells were then subculture for 68 h then (3-(4,5-Dimethylthiazol-2-yl)-2,5-
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diphenyltetrazolium bromide (MTT) was added and co-incubate for 4 h. After co-
incubation, cells were centrifuged and supernatant was removed and 150μl of DMSO 
were added and mixed. Absorbence was read by microplate reader (bench mark 
microplate reader, Bio Rad, Mississauga, Ontario, CA) at a wavelength of 695nm as a 
reference and 590nm as the absorbance.  
24 h post siRNA transfection, B16-F10 cells were re-plated in 96 well/plate in a number 
of 500/well. Cells were then subcultured in the indicated time point. 24 h, 48 h, 72 h, 96 h 
and 120 h after re-plating, cells were suspended and trypan blue was used for cell 
counting.  
 
4.3.6 Western Blot 
B16-F10 cells were plated into 24-well plates (1.5×105 cells per well) and allowed to 
grow overnight, to reach 80% confluence. Then cells were transfected with siBRAF or 
siScramble using lipofectamine for 72 h. Cells were washed and lysised by RIPA buffer 
(cells signaling technology, Danvers, USA) and total cellular protein was isolated from 
B16-F10 cells 72 h after transfection for western blot analysis using anti-mouse B-RAF 
(Abcam, Toronto, ON, CA) antibody.  
 
4.3.7 Preparation of Folate-lipo-siBRAF 
DOTAP, DPPC, cholesterols, and Folate-DSPE-PEG were mixed (3.75:13:13:1 molar 
ratio) to construct a folate receptor-targeting liposome. DSPE-PEG2000 (molar ratio to 
DOTAP was 3.75:4) was added after extrusion. The same reagents without the addition 
of folate were used to construct the control, non-folate liposome. The lipids were 
dissolved in chloroform in a glass tube, evaporated to complete dryness under vacuum. 
The lipid film was hydrated by the siRNA and protamine mixture. siRNA (targeting B-
RAF in distilled water was added to an equal volume of liposomes and protamine at a 
ratio of 600 nmol DOTAP:30 μg protamine:50 μg siRNA and incubated at room 
temperature for 10 min to form multilamellar liposomes and siRNA mixture. The 
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multilamellar liposome and siRNA mixture suspension was vortexed for 5 min followed 
by sonication for 2 min at 50°C in a bath sonicator, and the sonicated suspension 
extruded sequentially through polycarbonate membranes of decreasing pore size (0.4, 0.2 
and 0.1 mm diameter pores). The liposome nanoparticle solution was incubated (50°C, 10 
min; followed by cooling to 25oC) with DSPE-PEG2000 in a molar ratio to DOTAP of 
3.75:4 and 3.75: 5 to generate Folate and Non-folate liposomes, respectively. 
 
4.3.8 Folate liposome particle diameter and zeta potential 
Freshly prepared Non-folate and Folate liposomes were diluted with phosphate-buffered 
saline (PBS) and the mean particle diameter and surface charge (zeta potential) measured 
using a Zetasizer Nano Series (Malvern Instruments Ltd., UK) according to the 
manufacturer's protocol. 
 
4.3.9 In vitro uptake of liposomes loaded with Cy3 siRNA (Folate-
lipo-Cy3 siRNA)  
Freshly prepared mouse bone marrow cells (2x105) and B16-F10 cells ( 2x105/well) were 
plated in 12 well/plate and transfected with Folate-lipo-Cy3 siRNA, Non-folate-lipo-Cy3 
siRNA. Cells were harvested 4 h after transfection and Cy3 fluoresence were analyzed by 
flow cytometry. 
4.3.10 In vitro silencing of B-RAF in B16-F10 using Folate-lipo-
siBRAF 
B16-F10 cells were plated into 24-well plates (1.5×105 cells per well) and allowed to 
grow overnight, to reach 80% confluence. Then cells were transfected with Folate-lipo-
siBRAF or Folate-lipo-siScramble for 24 h. Total cellular RNA was isolated from B16-
F10 cells 24 h after transfection for qPCR analysis.  
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4.3.11 In vivo distribution of Folate-lipo-Cy3-siRNA 
C57/BL6 mice were used for melanoma inoculation using B16-F10 cells (2x105/ mice). 
Mice bearing melanoma were ready to be used when tumors reached the size of 500mm3. 
Non-folate-lipo-Cy3siRNA or Folate-lipo-Cy3 siRNA were injected intravenously into 
mouse tail veins (50 μg/ mouse). Mice were euthanized 6 h post-injection and organs 
(tumor, heart, liver, spleen, lung and kidney) were collected, rinsed with saline, snap-
frozen in liquid nitrogen, mounted for cryostat sectioning, and viewed using fluorescence 
microscopy.  
 
4.3.12 In vivo silencing of BRAF using Folate-lipo-siBRAF 
Folate-lipo-siBRAF and Non-folate-lipo-siBRAF were injected intravenously into mouse 
tail veins (50 μg/ mouse). Mice were euthanized 24 h later and tumors were collected for 
RNA isolation. All RNAs were prepared for qPCR analysis. 
 
4.3.13 Quantitative PCR analysis of B-RAF mRNA 
After in vivo treatment of mice or in vitro treatment of B16-F10 cells with liposomes 
loaded with control or B-RAF siRNA, total cellular or tissue RNA was isolated using 
Trizol (Invitrogen) and then used as a template for cDNA synthesis and quantitative PCR 
(qPCR). qPCR reactions using gene-specific forward and reverse primers (100 nM each) 
and SYBR Green PCR Master mix (Stratagene, La Jolla, CA,) in a Stratagene MX 4000 
Multiplex qPCR System. Primers used for the amplification of murine B-RAF and 
GAPDH were: B-RAF, 5’-CAATTGGCTGGGACACGGACAT-3’ (forward) and 5’-
TTGACAACGGAAACCCTGGAAAAG-3’(reverse); GAPDH, 5’-
TGATGACATCAAGAAGGTGGTGAA-3’ (forward) and 5’ -
TGGGATGGAAATTGTGAGGGAGAT-3’ (reverse). 
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4.3.14 Effect of Folate-lipo-siBRAF on in vivo mouse melanoma 
tumor growth 
B16-F10 mouse melanoma cells (2 x 105 cells) were suspended in 20 μl of PBS and 
injected s.c. and dorsally into each C57BL/6 mouse. Folate-lipo-siIDO or control 
liposomes encapsulates 100 g siRNA in a volume of 300 l were injected i.v. into mice 
2 days after injection with tumor cells and once per week thereafter. Control mice were 
identically injected with tumor cells followed, at the same time as injection of mice with 
Folate-lipo-siIDO, Folate-lipo-siScrambled, or non-folate-lipo-siIDO were also injected. 
Mice were checked for tumor formation on alternate days. Each tumor was measured by 
caliper and volumes estimated using the following formula: tumor volume = 0.5 x 
(width2) x (length).Mice were sacrificed 21 days after tumor inoculation and tumor was 
extracted for weighting.  
 
4.3.15 Immunohistochemistry staining of PCNA and Isolectin B4 in 
tumor tissue 
The melanoma tissue was fixed in 4% paraformaldehyde. Sections were incubated with 
primary antibody of antiPCNA and Griffonia Simplicifolia Lectin I (GSL I) – Isolectin 
B4 (IB4) (Vector, Burlington, Ontario, CA) mAb at 1:100 dilution. Then the sections 
were incubated with biotinylation secondary antibody for 45 min, followed by 
horseradish peroxidase-labeled streptoavidin at 37◦C for 45 min. Slices were finally 
developed with diaminobenzidene (DAB) and counterstained with hematoxylin. Slices 
were observed under microscopy in a magnification of 400x. Tunel staining was using 
TdT FragEL TM DNA Fragment Detect Kit (Billerica, MA, USA). Slices were observed 
under microscopy in a magnification of 200x.  
4.3.16 Statistical analysis 
Data are presented as means ± SEM. Control and experimental data were compared using 
one-way ANOVA followed by Newman-Keuls testing. P-values less than 0.5 were 
assumed a priori to indicate significant differences. 
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4.4 Results 
 
4.4.1 In vitro silencing and anti-proliferation assay on B16-F10 
cells by B-RAF siRNA 
 
B-RAF is an important cascade kinase in the classical MAPK pathway, which plays a 
crucial role in cell proliferation and survival. The mutation induced overexpression of B-
RAF and stimulates proliferation and survival, thus providing essential tumor growth and 
maintenance functions [24].Suppression of B-RAF mutations using chemical inhibitors 
are known to restrict tumor cell growth[25, 26]. In this study, we proposed to knock 
down B-RAF using siRNA, which could be more specific, fewer potential side effects 
and potent [27-30]. In order to detect the silencing efficacy and the inhibition ability of 
the B-RAF siRNA, in vitro siRNA transfection was applied on B16-F10 cells. siBRAF 
and siScramblewas were transfected in to B16-F10 cells and the B-RAF mRNA and 
protein expression levels were detected by qPCR and western blot respectively (Fig. 4-1, 
A and B). Based on the result, the mRNA expression level of B-RAF was knocked down 
by more than 80% (Fig. 4-1A) and the protein expression is also largely reduced in the 
siBRAF treated cells (Fig. 4-1.B). It demonstrates that the siBRAF could efficiently 
repress the B-RAF expression level in B16-F10 cells.  
To evaluate the inhibition efficacy of cell growth by siBRAF, a cell proliferation assay 
was used. After siBRAF and siScramble transfection, cells were subcultured and 
harvested at indicated time points, proliferation rate was determined by MTT assay and 
Trypan blue assay (Fig 4-1, C and D). According to the result, cell proliferation rate 
decreased up to 65% in 96 h (Fig. 4-1C) and the proliferation rate started to decrease 48 h 
after  
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Figure 4-1 In vitro gene silencing and anti-proliferation assay on B16-F10 cells by B-
RAF siRNA. (A&B) Determination of the silencing efficiency of B-RAF siRNA. 
siBRAF and control siScrambled were transfected by lipofectamine 2000 into B16-F10 
cells. (A) 24 h post transfection, cells were harvested and the total mRNA were isolated. 
The B-RAF expression level was determined by qPCR. (B) 72 h post transfection, cells 
were harvested and the B-RAF protein expression level was determined by western blot. 
(C&D) Determination of the anti-proliferation effect of B-RAF siRNA on B16-F10 cell. 
siBRAF and control siScrambled were transfected into B16-F10 cells by lipofectamine 
2000. (C) 92 h after transfection, MTT assay was conducted as described in Materials and 
Methods. 4 h post addition of MTT, absorbance was detected by microreader. (D) After 
transfection, cells were relocated from 12well plate into 96 well plate in a number of 
1000/well. Cells were harvested, stained with trypan blue and cell numbers were counted 
under microscope in 24 h, 48 h, 96 h and 120 h post transfection. 
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transfection. Thereafter, the difference between siScamble control and Non treatment 
control increased continually till 120 h, which implies that the silencing effect could be 
maintained within siBRAF transfected cells for at least 120 h (Fig. 4-1D).   
 
4.4.2 Characterization of Folate-lipo-siRNA 
Size and surface charge of liposomal nanopartticles are important for in vivo delivery 
particles, since larger size particle might ends up eaten by Kupffer and other 
reticuloendothelial cells rich organs, while negatively charged particles are repelled by 
siRNA and cell plasma membrane components [1, 18, 31]. To estimate the size and 
surface charge of the Folate-lipo-siBRAF, the diameter and the zeta potential (represents 
the surface charge) was detected (Fig. 4-2 A and B). Based on the result, the diameter of 
the folate-lipo-siBRAF was around 160nm (Fig. 4-2A) and the zeta potential is around 37 
mV (Fig. 4-2B). According to the previous report [32], the size and the surface charge of 
the prepared liposomes were suitable for potential in vivo siRNA delivery.  
The rapid degradation of siRNA is another major hurdle of siRNA in vivo delivery [33, 
34]. To determine whether siRBAF were encapsulated and protected by the Folate 
liposomest, a degradation assay was applied using 90% FBS mixing with folate-lipo-
siBRAF, Non-folate-siBRAF or naked siBRAF. Compare to the naked siBRAF, Folate-
lipo-siBRAF and Non-folate-siBRAF could protect siBRAF from being degraded at least 
48 h (Fig. 4-2 C), which implies that both the Folate and Non-folate liposome provide 
protection against systemic degradation of siRNA by nucleophiles and nucleolytic 
enzymes, and that addition of folate to liposomes does not influence the protective 
capacity. 
4.4.3 In vitro targeting assay of Folate-lipo-Cy3-siRNA and gene 
silencing of B-RAF 
FRs are known to express in many malignant tumor cells but not normal cells [18]. To 
determine the preferentially targeting efficacy of the Folate-lipo-siRNA towards 
malignant cells, an in vitro cell targeting assay was applied. Freshly cultured bone  
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Figure 4-2 Preparation and characterization of Folate-lipo-siRNA. (A & B) 
Determination of the size and zeta potential of Folate-lipo-siRNA.Folate-lipo-siRNA and 
non-folate-lipo-siRNA were prepare as described in the Materials and Methods. The size 
(A) and the zeta potencial (B) of Folate-lipo-siRNA and non-folate-lipo-siRNA were 
measured by zetasizer. (C) Serum protection assay. Naked siRNA, Folate-lipo-siRNA, or 
non-folate-lipo-siRNA were incubated with 90% FBS at 37 oC at various time points. 1, 4, 
8, 24 and 48 h post incubation, liposomes that encapsulated siRNA were harvested by 
Trizol, siRNA  was isolated by chloroform and isopropanol method, then visualized by 
15% page gel electrophoresis. The data presented one of three independent experiments. 
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marrow cells (non-FR-expressing controls) and consistently FR-expressing B16-F10 cells 
were transfected with both Folate-lipo-Cy3-siRNA and Non-folate-Cy3-siRNA.The 
intensity of the Cy3 fluorescent in cells were detected by Flow cytometry (Fig. 4-3 A). 
From the result, we observed much higher uptake of Folate-lipo-Cy3-siRNA in tumor 
cell B16-F10 when compare to normal bone marrow cells, while similar uptake of Non-
targeting-Cy3-siRNA was observed in both cells. While there are large differences 
between Folate-lipo-Cy3-siRNA and Non-folate-Cy3-siRNA in FRs expressing cells, the 
difference is trivial in non FRs expressing cells. It illustrated that, most of the uptake of 
Folate-lipo-Cy3-siRNA were FRs expression associated. While the characteristics of the 
Folate-lipo-Cy3-siRNA and the Non-folate-lipo-Cy3-siRNA do not influence much of 
the transfection rate, the addition of folate to liposomes makes large difference in targeted 
delivery capability.  
To evaluate the in vitro silencing ability of Folate-lipo-siBRAF, B16 cells were used and 
transfected with Folate-lipo-siScramble and Folate-lipo-siBRAF respectively. 24 h later, 
cells were harvested and the BRAF expression was determined by qPCR. Compared to 
Folate-lipo-siScramble treatment group, BRAF expression in cells treated with Folate-
lipo-siBRAF was significantly knocked down to 70% (Fig. 4-3B), which demonstrates 
that Folate-lipo-siBRAF is potent for in vitro silencing. 
 
4.4.4 Bio-distribution of Folate-lipo-Cy3-siRNA and in vivo gene 
silencing of B-RAF  
Cell surface receptors for folic acid are generally overexpressed in human cancer cells 
[35]. In mouse melanoma, B16-F10 consistently expresses FRs. To determine the in vivo 
targeting efficacy of Folat-lipo-siBRAF, melanoma bearing mice were used for the in 
vivo targeting assay. Mice inoculated with B16-F10 melanoma and bearing melanoma 
tumors were intravenously injected with Folate-lipo-Cy3-siBRAF or Non-lipo-Cy3-
siBRAF. Based on the intensity of the fluorescent, an overall stronger fluorescent in 
tumor tissues that administrated with Folate-lipo-Cy3-siBRAF than the tumor tissues that  
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Figure 4-3 In vitro targeting assay of Folate-lipo-Cy3-siRNA and gene silencing of 
BRAF. (A) Transfecting efficacy of Folate-lipo-Cy3-siRNA detected by flow cytometry. 
B16-F10 cells and freshly prepared bone marrow cells were transfected by Folate-lipo-
Cy3-siRNA and non-folate-lipo-Cy3-siRNA. 4 h after transfection, the cells were 
harvested and the fluorescence of encapsulated Cy3-labeled siRNA was detected by flow 
cytometry. (B) Gene silencing of BRAF using Folate-lipo-siBRAF. B16-F10 cells were 
transfected by Folate-lipo-siBRAF and Folate-lipo-siScramble. 24 h after transfection, 
cells were harvested and  the mRNA were isolated. The BRAF expression of B16-F10 
was detected by qPCR. **p<0.01 
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administrated with Non-lipo-Cy3-siBRAF can be observed. Strong fluorescence was 
observed in liver while little was seen in spleen. No fluorescence was detectable in other 
vital organs. Moerover, the fluorescence in tumor tissues are more collective than those 
in liver and spleen, which might attribute to the disorganized vascularization in tumor 
tissue (Fig. 4-4A). Although the strongest fluorescence can be observed in liver, strong 
fluorescence could be seen in tumor tissue in Folate-lipo-Cy3-siBRAF administrated 
mice. Remarkably, the flourecence in tumor tissue of the Folate-lipo-Cy3-siBRAF 
administrated mice is much stronger than the tumor tissue of Non-lipo-Cy3-siBRAF 
administrated mice, which illustrated that Folate-lipo-siBRAF is able to enhance the 
delivery of the siRNA into tumor tissue and the addition of folate to the liposomes could 
increase the tumor delivery efficacy.  
For efficient drug delivery, a carrier system should facilitate not only tumor localization 
but also intracellular access [35]. To estimate the ability of the Folate-lipo-siBRAF in 
helping the encapsulated siRNA reaching the targeted cells and therefore induce silencing 
of the intended gene, in vivo tumor silencing assay was applied. Folate-lipo-siBRAF and 
Folate-lipo-siScramble were intravenously injected into melanoma bearing mice. 24 h 
post administration, mice were sacrificed and tumor tissues were extracted for qPCR. 
Based on the qPCR result, the BRAF mRNA expression level has been largely knocked 
down when compare to Non treatment control and scramble control (Fig. 4-4B), which 
proves that Folate-lipo-siBRAF is capable in repressing the BRAF expression level in 
vivo in tumor tissue.  
 
4.4.5 Anti-tumor growth of melanoma by Folate-lipo-siBRAF. 
The inhibition of B-RAF in B-RAF overexpressing malignant cells would restrict the 
growth of the tumor [26]. To determinate whether the Folate-lipo-siBRAF is able to 
restrict tumor growth in vivo, Folate-lipo-siBRAF was applied as a therapy for melanoma 
bearing mice. Folate-lipo-siBRAF, Non-folate-lipo-siBRAF and Folate-lipo-siScramble 
was intravenously injected to the tumor bearing mice two days after tumor inoculation  
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Figure 4-4 Bio-distribution of Folate-lipo-Cy3-siRNA and in vivo gene silencing of B-
RAF. (A) Bio-distribution of Folate-lipo-siRNA. Mice were i.v injected with Folate-lipo-
Cy3-siRNA and non-folate-lipo-Cy3-siRNA. 6 h post administration, mice were 
sacrificed and tumor tissues, liver, spleen, lung, kidney and heart were extracted for 
frozen section. The red fluorescence of Cy3-labeled siRNA in the various tissue sections 
were observed under a fluorescent microscope. The data presented one of three 
independent experiments. The magnification was 10x. (B) In vivo gene silencing by 
Folate-lipo-siBRAF. Folate-lipo-siBRAF or Folate-lipo-siScrambled were i.v injected 
into C57/BL6 mice. 24 h after injection, mice were sacrificed and the B-RAF expression 
in tumor tissue was detected by qPCR. **p<0.01. 
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and once/week thereafter. Base on the tumor size measurement data, mice treated with 
Folate-lipo-siBRAF have significantly smaller tumor size in the same day after tumor 
inoculation when compare to Non treatment control, Non-folate-lipo-siBRAF and Folate-
lipo-siScramble (Fig. 4-5 A). Mice treated with Non-folate-siBRAF also had a relatively 
smaller tumor size when compare to Non treatment control and Folate-lipo-siScramble, 
however, the difference was not significant.  
21 d after tumor inoculation, mice were sacrificed and tumors were extracted for weight 
evaluation. Mice in Folate-lipo-siBRAF treatment groups have significantly small tumor 
weight as comparing to Non treatment control, Non-folate-lipo-siBRAF and Folate-lipo-
siScramble treatment groups (Fig. 4-5 B). It demonstrated that Folate-lipo-siBRAF is 
able to restrict tumor growth and the therapeutic effect is much better when there folate is 
added into the delivery system.  
 
4.4.6 Anti-proliferation, anti-vascularization in melanoma by 
Folate-lipo-siBRAF 
The inhibition of B-RAF would induce less proliferation and more apoptosis, which 
serves as the major drive of tumor growth restriction [29]. Proliferating cell nuclear 
antigen (PCNA) was identified as the processivity factor of DNA polymerase delta 
(PFDPδ) [36, 37], which is part of a donut-shaped multi-protein complex playing a role 
in DNA repair and replication [38, 39]. It is a well-conserved protein in all eukaryotic 
species which is a processivity factor of DNA polymerased that required for DNA 
synthesis [40-43]. To determine whether Folate-lipo-siBRAF treated tumor tissue were 
restricted in proliferation, immunochemistry staining was applied. Based on the result, 
Folate-lipo-siBRAF treated tumor tissue has much less PCNA (Fig. 4-6 A)  expression 
than Non treatment control, Non-folate-lipo-siBRAF and Folate-lipo-siScramble 
treatment groups, which illustrates that the Folate-lipo-siBRAF is able to induce in vivo 
anti-proliferation in tumor, and therefore restrict tumor growth. There is trivial difference 
between the Non treatment control, Non-folate-lipo-siBRAF and Folate-lipo-siScramble 
treatment groups, which implies that although the fluorescence in tumors can be seen in  
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Figure 4-5 Anti-tumor effects of Folate-lipo-siBRAF. (A & B) Experimental treatment of 
murine melanoma using Folate-lipo-siBRAF. Folate-lipo-siBRAF, or non-folate-lipo-
siBRAF, or Folate-lipo-siScramble was i.v. injected into C57/BL6 mice two days after 
tumor inoculation. Treatments were repeated once a week thereafter. Tumor size (A). 
Tumors in treatment and control mice were monitored every three days. Tumor weight 
(B). Tumours in different experimental groups or control groups were extracted and 
weighted in day 21 after mice were sacrificed. Each point represents the weight of 6 mice 
in each group. Results represent 1 of 3 experiments. **p<0.05. 
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Figure 4-6 Anti-proliferation effects by Folate-lipo-siBRAF in melanoma. Immune 
histochemistry staining of PCNA in tumor tissues. 21 days after tumor inoculation, mice 
in different experimental groups were sacrificed and the tumor tissues were harvested for 
immune histopathology staining. (A) PCNA positive cells in Non-treatment, Folate-lipo-
siBRAF, non-folate-lipo-siBRAF, or Folate-lipo-siScramble treated tumor tissue were 
displayed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
163 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Untreated F+ Scramble F‐ BRAF F+ BRAF
PCNA
A
164 
 
Non-folate-lipo-siBRAF, the uptake of the liposome is not efficient enough to restrict the 
tumor growth. Lectins are specific carbohydrate-binding proteins that have been applied 
in identifying the glycosylation status specifically in a variety of tissues [44-46]. Within 
the lectins family, IB4 has been shown to be useful for analysis of microvascular 
structure and function. IB4 binds on various cells that express α-galactosyl residues, 
including endothelial cells [45-48] in normal mouse, rabbit, rat and human tissues [49]. 
IB4 also has been used to identified neovascular structures specifically within tumor 
vascular networks [50]. To determine whether Folate-lipo-siBRAF treated tumor tissue 
were restricted in vascular network or not, IB4 was used to stain the melanoma tissues in 
various experimental groups (Fig. 4-7B). According to the result, mice treated with 
Folate-lipo-siBRAF have much less microvasculature than the Non treatment control, 
Folate-lipo-siScramble and Non-folate-lipo-siBRAF treatment group, which implies that 
the in vivo silencing of BRAF is able to restrict the vascular network. Although the 
melanoma tissues treated with Non-folate-lipo-siBRAF have slightly less endothelial 
cells, the difference between the Non treatment group and Folate-lipo-siScramble control 
group is trivial, which illustrates that with the folate ligand, the liposomal system 
provides better therapeutic effect.  
 
4.5 Disscussion 
Melanocytes originate from highly motile cells with enhanced survival properties, which 
attribute to the high aggressiveness, high metastasis and high resistance to cytotoxic 
agents. When compare to other malignancies, melanoma is more resistance to 
chemotherapy, radiotherapy and immunotherapy, which is a major barrier for successful 
treatment [52]. Targeted therapies that focus on those which cancer cells have come to 
depend for progression are most attractive[53]. B-RAF is implicated in several aspects of 
melanoma induction and progression. Several years after B-RAF mutation was 
discovered, the first selective inhibitors, vemurafenib, has entered clinical trials. However, 
after the regression in the early course of the therapy was recorded, it is observed that 
resistance to therapy emerged in the subsequent and follow-up treatment. The response 
duration ranged from 2 to >18 months. Now, a lot of research groups have focus on the  
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Figure 4-7 Anti-vascularization effects by Folate-lipo-siBRAF in melanoma. (B) 
Immuno histochemistry staining of IB4. 21 days after tumor inoculation, mice in different 
experimental groups were sacrificed and the tumor tissues were harvested for immuno 
histopathology staining. IB4 positive endothelial cells  in Non-treatment, Folate-lipo-
siBRAF, non-folate-lipo-siBRAF, or Folate-lipo-siScramble treated tumor tissue were 
displayed. 
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resistance mechanism in B-RAF therapy [53]. siRNA could be an alternative choice: it is 
potent, highly specific to the targeting mRNA sequence and less toxic or size effect. 
Moreover, siRNA has more potential in controlling more than one gene’s expression, 
which offers great potential for “personal” cancer therapy [54]. In our study, we observe 
a potent silencing of B-RAF expression by siRNA and a significantly decrease of cell 
proliferation in vitro and tumor growth in vivo.  
However, in vivo application of siRNA faces many challenges. First, siRNA is not stable 
in circulation. Second, to achieve effective in vivo RNAi application, tissue barrier and 
intracellular delivery have to be overcome. Third, cell entrance and endsomal escape are 
the crucial issues for siRNA delivery. Fourth, siRNA in tumor delivery is especially 
difficult since tumor vasculature is poorly organized, tortuous, defective and location-
dependent heterogeneity. Therefore, when compare to normal tissue, tumors have lower 
blood flow, higher flow resistance and as a result, lower presentation of siRNA to tumors. 
Meanwhile, tumor blood vessels have discontinuous endothelium, which makes it leaky 
and permeable to larger size molecules (100 – 780nm). These properties facilitate larger 
siRNA combined nanoparticles (e.g., 100nm) extravasation through diffusion and 
convection in tumors and realize passive tumor targeting [55-59]. Thus, an effective 
delivery system is needed.  
Folate based targeting systems already be successfully applied as a therapeutic agents or 
imaging agents[60, 61]. Comparing liposomes with other carrier delivery systems, 
liposomes offer multiple advantages for drug delivery, including their biocompatibility, 
biodegradability and safety. Further, liposomes are able to accumulate within tumor 
tissue due to the passive accumulation of colloidal macromolecules of approximately	
40kDa and above in tumors, which cause the enhanced permeation and retention effect 
(EPR) [62]. The accumulation of liposomes in tumor tissue could be improved through 
the use of receptor targeting moieties that are either postconjugated to the surface of 
liposomes or attached to lipids that become incorporated within the liposomal bilayer[31]. 
Since FRs are generally overexpressed on human cancer cells [21, 43, 63, 64] and the 
affinity of FRs will not be affected when PEG covalently connected the -carboxyl [20, 
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65] of folate. Therefore, liposomes that included folate conjugated lipids have been 
considered as promising non-live vectors for tumor targeted delivery purposes. 
In our study, we observed a protective effect of the folate liposome to the encapsulated 
siRNA and a significantly preferential targeting effect in Folat-lipo-siBRAF, which offer 
a promising delivery system for siRNA tumor delivery.  
However, excessive cationic charge would induced the the first-pass clearance by lung 
and liver, which offer strong reticuloendothelial system (RES) that allows strong 
interaction between the cationic surface of the liposome-siRNA complex (lipoplex) and 
the plasma proteins [2, 3, 66]. In our study, we observed an intense fluorescence in liver, 
however, no fluorescence in lung. What’s more, a relative strong fluorescence could be 
seen in tumors, which implies that the liposome we generated is not too “cationic” that 
enable it better escaping the RES and further being delivery into tumor. One of the 
methods to shield the charge of lipoplexes is to add additional neutral membrane bilayer 
outside the lipoplex[40, 67]. In the same purpose, in our procedure of generating the 
lipoplex, we added DSPE-PEG lipids, which is a neutral lipids, after extrusion and before 
it could be used. In fact, the in vivo study results show that the liposome was able to 
deliver siBRAF into B16-F10 melanoma and silenced the B-RAF expression in tumor, 
with the silencing efficacy potent enough to restrict the tumor growth.  
Human v600E B-RAF, which is a mutation of B-RAF that leads to the overexpressiong of 
B-RAF, stimulates constitutive ERK signalling, stimulating proliferation and survival and 
providing essential tumour growth and maintenance functions [68]. v600EBRAF also 
contributes to neoangiogenesis by stimulating autocrine vascular endothelial growth 
factor (VEGF) secretion. It has been shown that, the blockade of RAF/MEK/ERK 
pathway could induce apoptosis, especially in B-RAF V600E melanoma cells [69-71]. 
Apoptosis is a frequent sign of the response to B-RAF inhibitor, such as 
PLX4032/RG7204, an analogue to PLX4720, which suggesting that it is the major 
biological consequence of inhibition of mutant B-RAF [51]. Based on the immune-
histopathology staining, we observed a similar anti-tumor effect with human that by 
reducing the BRAF expression in tumor cells, the proliferation of the tumor cells as 
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decreased and less endothelial cells were observed, which implies the anti-proliferation 
effects, anti-vascularization and increase apoptosis effects of the Folate-lipo-siBRAF.  
In summary, we report here a folate receptor expressing malignant cells targeting systems 
to delivery B-RAF siRNA can efficiently block the B-RAF expression in tumor cells in 
vitro and tumor tissues in vivo. Treatment of Folate-lipo-siBRAF results in significantly 
reduced tumor size and tumor weight; decreased tumor cells proliferation, reduced tumor 
tissue capillary and increase tumor cells apoptosis in vivo.  
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Chapter 5  
5 General Discussion 
5.1 General Discussion 
The studies throughout this thesis focus on examining the validation of different RNAi 
therapies for different diseases. To study the validation of RNAi as a potential therapy, 
two disease models and four specific siRNA sequences were applied in Chapters 2-4. In 
each chapter, a specific RNAi therapy was examined: 
 Validation of transdermal delivery by a novel topical delivery reagent of siTNFα 
and siMyD88 in contact hypersensitivity therapy.  
 Determination of whether mannosed liposomes encapsulating siIDO is a good 
immune therapy for melanoma. 
 Determination of whether folated liposomes encapsulating siBRAF is a good 
therapy for melanoma.  
In Chapter 2, we describe development of a topical delivery reagent for efficient delivery 
of siRNA into dermis as a potential therapy for ACD. The current standard for ACD 
treatment involves local application of corticosteroids that target lymphocyte activation. 
However, this method results in many unwanted side effects. These side effects can 
become amplified when addiction to cutaneous application requires increasing dosages. 
We propose that topical application of siRNA could alleviate some of these problems 
since it directly contacts the disease site, restricts toxicity to the application area, and is 
user-friendly. However, as previously discussed, effective topical siRNA delivery 
requires penetration-enhancing techniques to infiltrate the SC and reach target cells. 
There are two routes of passive diffusion for permeation of the SC: the trans-epidermal 
route and the trans-appendageal route. The trans-epidermal route can be further broken 
down into two pathways: polar or hydrophilic compounds prefer passing through the 
stacked layers of corneocytes, while lipophilic compounds favour travelling through the 
intercellular spaces [1, 2]. Although the intercellular space route only occupies 1% of the 
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available area [3], it is thought to be the predominant route of entry through the stratum 
corneum [4]. In 1997, Menon and Elias suggested the “aqueous pore pathway” [5], which 
states that the discontinuous lacunar domains in the lipid matrix will expand and become 
a continuous pathway when the SC is being hydrated. With the removal of the 
permeabilizing agent, the continuous lacunar domains will recover to a fragmented state 
[6].  
The trans-appendageal penetration route is through skin appendages such as sweat glands, 
sebaceous glands, and hair follicles. However, these pathways only occupy a small area 
of the total cutaneous surface, so they play a limited role in drug diffusion [7, 8]. Of the 
possible appendages in skin, the hair follicle is likely to play the largest role due to its 
relatively large size, and the presence of sebum in the duct of the pilosebaceous gland 
could facilitate the diffusion of lipophilic drugs [3]. Many studies using various methods, 
such as confocal laser scanning microscopy, biopsies, and tape stripping techniques have 
been used to study the penetration of drug molecules through the hair follicles [7]. Under 
the stratum corneum are the layers of the epidermis, which is 50-100 μm in thickness in 
total. These layers contain live, nucleated cells that have much less resistance to diffusing 
compounds [3]. Extremely hydrophilic or lipophilic molecules might have difficulty in 
penetrating this portion of the epidermis since the cells form tight linkages, limiting 
diffusion through the cell membranes and cytosol [9]. Based on the data in Chapter 2, it is 
possible that the novel topical reagent penetrates the SC via both trans-epidermal and 
trans-appendageal routes. Under the fluorescent microscope, fluorescence could be seen 
distributed evenly throughout both the SC layer and other layers of cells in the dermis, 
which implicates the trans-epidermal route. Stronger fluorescence could also be seen in 
hair follicles illustrating the trans-appendageal route. By utilizing both routes, the novel 
reagent could reach higher transdermal ability. The topical reagent is neither too 
hydrophilic nor lipophilic, which facilitates its penetration through the living cell layers 
of the dermis. Helping siRNA penetrate the living cells of the dermis, including 
Langerhans cells in the stratum spinosum, could alter their biologic function through 
silencing. 
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Tumor necrosis factor (TNF) is a systemic inflammation-induced cytokine and a member 
of a group of cytokines that stimulate the acute phase reaction. It can be produced by 
CD4+ lymphocytes and NK cells, but is mainly produced by activated macrophages (M1). 
The primary role of TNF is in regulating immune cells. It can induce fever, apoptotic cell 
death, sepsis (by inducing IL1 and IL6 production), cachexia, inflammation, and it can 
inhibit tumorigenesis and viral replication. TNFα is one member of the TNF family of 
receptor ligands. It has multiple biological activities, including immunomodulation and 
oncostatic, osteolytic, pirogenic, proinflammatory, and other activities [10].  
The first TLR adaptor molecule discovered was MyD88. It is induced by IL-6 and was 
isolated from M1 myeloleukaemic cells differentiated into macrophages by IL-6 
treatment, and characterized as a myeloid differentiation response gene [9]. MyD88 is a 
TIR domain-containing cytoplasmic protein. The pathway activated by the TIR domain 
of TLRs that recruits MyD88 has been widely studied [11]. With the exception of TLR3, 
MyD88 mediates signaling by all TLRs [1]. MyD88 interacts with IL-1 receptor 
associated kinase 4 (IRAK-4), causing IRAK-4 and IRAK-1 to form a complex which 
leads to its phosphorylation and activation [2]. IRAK-4 and IRAK-1 then dissociate from 
the complex and interact with tumour necrosis factor (TNF) receptor-associated factor-6 
(TRAF-6), which then recruits transforming growth factor-activated kinase-1 (TAK-1)-
binding protein-1 (TAB-1) and TAB-2 to the complex. This leads to the phosphorylation 
and activation of the kinase TAK-1 [4]. Next, TAK-1 activates kinases upstream of p38 
and JNK and the inhibitory κB (IκB) kinase (IKK) complex leading to NF-κB activation 
[3].  
Once established, ACD is a lifelong disease. Prevention and avoidance of the causative 
agent (hapten) is critically important. Prevention and avoidance are of even greater 
importance for patients exposed to more than one sensitizer or extremely diffuse 
sensitizers. Methods that limit hapten penetration may help to reduce hapten-peptide 
complex formation, thus limiting the allergic reaction. However, the efficacy of these 
methods is limited. Most of the therapeutic approaches against ACD aim at blocking T 
cell transmigration to skin, reducing leukocyte activation, or preventing keratinocyte-
dependent amplification of the inflammatory response.  
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With understanding of the mechanisms that govern T cell recruitment, many compounds 
that could inhibit the leukocyte-endothelial cell interactions have been developed and 
implemented in clinical trials. This approach has advantages in selectively targeting T 
cell subpopulations while maintaining immunoprotection in other situations. However, it 
is limited by the redundancy of the mechanisms involved in T cell extravasation and 
positioning into the skin.  
Other proposed targets in treatment of ACD include selectins (which mediate initial 
rolling of leukocytes over the endothelium), adhesion molecules, and chemokine-
chemokine receptor pairs [12-14]. However, strategies that interfere either with selectin 
functions or the modulation of the post-trascriptional glycosylation of selectin ligands 
have all had disappointing results when tested in humans [15].  
Another attractive strategy is to target chemokine receptors in selective leukocyte 
subpopulations. Unfortunately, approaches to block chemokine-receptor axes have 
provided inconsistent results [16]. 
Most of the therapies for ACD are currently based on systemically or locally 
administrated drugs that target lymphocyte activation. Topical application of 
corticosteorids remains the mainstay treatment of ACD. More severe ACD reactions 
often require a systemic immunosuppressive treatment, typically based on a systemic 
corticosteroid regimen or cyclosporine administration. Therapeutic effectiveness of 
cyclosporine in ACD results from its dramatic effects on T cell functions, as well as on 
cytokine release [6].  
My study focuses on one of the most important cytokines in ACD (TNFα) as well as a 
vitally important molecule in mediating transduction of innate immune signaling 
(MyD88). In accord with reported data [7, 8], my study shows that a single treatment of 
TNFα alone is not sufficiently potent to alleviate symptoms of ACD, with the exception 
of a reduction in swelling.  
In Chapters 3 and 4, I discuss two potential RNAi immune therapy for cutaneous 
melanoma. Melanoma is the most deadly form of skin cancer. If diagnosed early, 
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melanoma can be cured by surgical resection and approximately 80% of cases are dealt 
with in this manner. Nevertheless, the metastatic nature of melanoma malignancies 
results in high resistance to therapy and poor prognosis. Malignant melanoma patients 
with metastatic disease have a median survival of 6 months and a 5 year survival of less 
than 5%, illustrating the pressing need for new and better treatment. 
Many factors could contribute to melanocyte oncogenesis, including mutations in critical 
growth regulatory genes, the production of autocrine growth factors, and the loss of 
adhesion receptors [12]. As melanocytes progress toward malignancy they proliferate and 
spread, forming a naevus or common mole. The proliferation of melanocytes can be 
restricted to the epidermis (junctional naevus), dermis (dermal naevus), or overlapping 
components of both (compound naevus). Naevi are benign but have the potential to 
progress to radial-growth-phase (RGP) of melanoma, which is an intra-epidermal lesion 
that can involve some local micro-invasion of the dermis. RGP cells can further progress 
into vertical-growth-phase (VGP), which is a more dangerous stage where cells tend to be 
more invasive and metastatic and have nodules or nests of cells invading the dermis. 
Melanocytes or naevi can directly develop to RGP or VGP, and cells in RGP or VGP can 
progress into metastatic malignant melanoma.  
There are four main clinical subtypes of melanoma [12]. Nodular melanoma consists of 
raised nodules without a significant flat portion. Acral lentiginous melanoma (ALM) is 
not associated with UV exposure since it is usually found on the palms of the hands, soles 
of the feet, and in the bed of fingernails or toenails. In non-Caucasian populations, ALM 
accounts for 50% of melanomas [13]. Lentigo maligna tends to correlate with chronic sun 
exposure since it occurs in the elderly on sun-exposed skin regions. It is generally flat in 
appearance. Superficial spreading melanoma (SSM) is the most common form of 
melanoma. It linked to severe sunburn, especially at an early age. It is usually flat with an 
intra-epidermal component. SSM accounts for the remaining 50% of melanomas in non-
Caucasians. It is the third most common cancer in young people in the UK and USA [14, 
15].   
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Melanoma is recognized as an immuno-responsive type of tumour since T lymphocyte 
infiltration into the tumour correlates with improved patient survival [17]. A longstanding 
conventional therapy for melanoma involves administration of interleuklin-2 (IL-2). IL-2 
is thought to exert antitumour effects by enhancing the host’s antitumour response and by 
inducing T cell activation. IL-2 treatment alone results in a response in only 
approximately 15% of cases. Moreover, the use of IL-2 in high doses is associated with 
considerable mortality, attributed to the development of gastrointestinal, cardiovascular, 
renal and neurological toxicities including vascular leakage syndrome where fluid 
accumulates within the lung and liver. Another therapeutic approach is to use type I 
interferons (IFN-α, IFN-α2). In some studies, IFN-α and IFN-α2 treatment has proven 
beneficial in prolonging disease-free survival when applied in an adjuvant setting. A 
modified IFN-α2 treatmment has entered a phase III study where its use as a single 
agent versus combination with other treatments in an adjuvant approach [18].  
In spite of the demonstrated capacity of the immune system to mount an antitumour 
attack, tumours are still able to evade that attack, a process known as immune escape. 
IDO is one important factor aiding escape of tumours from immune attack. In Chapter 3, 
I described application of man-lipo-IDO, which targets a broad range of mannose 
receptor-expressing APCs, to silence IDO expression in those APCs to achieve a 
therapeutic effect. This preferential targeting strategy has both advantages and 
disadvantages. One disadvantage is the case of non-specific binding to non-mannose-
receptor-expressing cells and tissues: this increases the required dose of siRNA to be 
delivered due to intended cells and tissues, where silencing of the unintended gene would 
prove inconsequential or, perhaps, deleterious. However, an advantage of targeting not 
only DCs but all mannose receptor expressing APCs is that it might offer broader 
therapeutic effects that contribute more than expected. This notion stems from the fact 
that DCs and IDO-expressing DCs represent only a very small subpopulation of immune 
cells. Overall, a broader APC targeting approach could be more effective than extremely 
specific targeting strategies.  
Melanoma is an aggressive tumour that is resistant to all standard anticancer therapies. 
Resistances mechanisms in melanoma are complex since a wide range of antineoplastic 
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treatments are ineffective at killing melanoma cells. In this tumour type, it is suggested 
that drug resistance is due to the inherent malignant behavior of melanoma cells rather 
than acquired genetic alternations selected for over therapy [19]. The success of systemic 
therapy for metastatic melanoma has been minimal [20]. The identification of mutant B-
RAF as a major driver of melanoma progression appeared as a breakthrough in 
melanoma therapy [21]. The development of vemurafenib, a B-RAF kinase inhibitor with 
high specificity for mutant B-RAF was a turning point [22, 23]. Vemurafenib progressed 
rapidly through early phase trials and significant levels of tumor shrinkage were seen in 
patients whose melanomas harbored B-RAF V600E mutations [24, 25]. The overall 
response rate for vemurafenib was 48% compared with 5% for dacarbazine [26]. 
However, almost all patients treated eventually developed resistance and most tumours 
progressed on therapy [25-27]. 
In Chapter 4, a lipid-based delivery system that targets oncogenic gene B-RAF was 
applied as a strategy for treatment of melanoma. We found that using cationic lipid 
delivering siRNA and preferentially targeting tumor cells is an effective way to treat 
melanoma in the xenograft model we employed. It restricted tumor growth by inhibiting 
tumor cell proliferation, reducing angiogenesis, and promoting tumour cell apoptosis. In 
my study, however, there are still many areas that can be improved upon. First, it was 
observed that the fate of most injected liposomes was the liver, and this accumulation of 
therapeutic agent in non-target tissue remains a major barrier to improving the efficacy of 
this therapy. Although most intravenously-administered drugs share this limitation, we 
believe our system could be improved by further optimizing a novel combination of 
lipids within the liposome or adjusting the ratio of already-used components. Second, 
using a human xenograft model in immune-deficient mice could more realistically mimic 
a clinical setting. Regardless of these limitations, we have established that RNAi therapy 
could be a potential alternative for melanoma treatment.   
Compared to other methods such as use of chemical inhibitors as therapeutic agents and 
use of dominant-negative mutants to explore gene function, siRNA provides many 
advantages. First, siRNA can be designed to target any class of genes (including both 
protein-coding and non-coding RNAs) and can potentially silence the expression of any 
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gene. Second, while constructing dominant negative mutants is time-consuming, siRNA 
can be easily synthesized for direct administration or cloned into expression vectors for 
expression in cultured cells in vitro or xenografts or induced tumours in vivo[28]. Third, 
compared to both chemical inhibitors and dominant-negative mutants, siRNA-mediated 
silencing is more specific and less toxic. Fourth, human tumours display different gene 
expression profiles not only compared to normal tissue but also compared to each other. 
Such heterogeneity would suggest the benefit of using a “personal” therapy approach. 
The ability of detecting pathways that malignant tissue depends on and specifically 
knocking them reveals the potential of RNAi to be a “personal” cancer therapy with 
capacity to be specifically tailored to therapy of each individual patient, depending on the 
molecular profile of their tumour [29, 30]. Finally, while most chemical inhibitors and 
dominant-negative mutants are designed to inhibit only specifically-identified enzymatic 
or other activities of over-expressed proteins in tumors (i.e., those attributable to specific 
sub-regions of the protein, without affecting other, unidentified activities that could be 
mediated by regions unaffected by targeted mutations or association with chemical 
inhibitors), siRNA prevents production of the protein entirely, thus eliminating all 
activities, both known and unknown. This makes RNAi a potent tool to inhibit function. 
For the reasons outlined above, RNAi therapy is, overall, an attractive alternative to 
knock down overexpressed genes involved in cancer progression and metastasis, 
particularly where conventional treatment fails [31]. SiRNA has the potential to be more 
effective than some current treatments of cancer because it targets the genetic material at 
the core of the problem, while many other treatments aim only at reducing clinical 
symptoms [32].  
A major barrier to clinical application of siRNA is sub-optimal in vivo delivery. To 
overcome this difficulty, many efforts have been exerted on developing a specific, 
efficient and safe delivery method. At the same time, to validate it as a therapy, the 
choice of target and the specific siRNA sequence itself are also vitally important.   
Non-virus in vivo delivery strategies can be classified into two groups based on the route 
of administration: local and systemic [33]. Local administration could be applied on 
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easily accessible tissues. Local application of siRNA could directly deliver siRNA into 
target tissues, which allows the accumulation of the proper siRNA amount and 
substantially targeted release in the intended tissue. In our studies, we also used local 
application of siRNA on skin for the treatment of ACD. Later on, we also discuss the 
validation of using cationic lipids to achieve the systemic delivery of siRNA in treating of 
melanoma [34].  
Preformed cationic liposomes are among the most efficient in vitro transfection reagents 
for nucleic acids/siRNA. The negatively charged phosphate backbone of siRNA can be 
complexed electrostatically with cationic lipid, which contributes to its high efficacy [35, 
36]. In addition, the net positive charge complexes can avidly bind to anionic 
proteoglycans on cell surfaces, facilitating their uptake [36-38].  
However, most of the commonly used cationic lipids have failed in clinical trials due to 
poor in vivo performance because of excessive cationic charge, which results in low in 
vivo transfection efficiency, toxicity, immune activation, and unfavorable biodistribution. 
The lipoplexes are rapidly cleared when systemically administered because they 
accumulate in the capillary bed of first-pass organs such as the lungs [39, 40]. After this 
first clearance, hepatic elimination becomes the major factor for the lipoplexes 60 
minutes after injection, just after the lipolexes redistribute from lung to liver [41]. In 
many cases, lipoplexes would strongly interact with plasma proteins, leading to 
entrapment and clearance by the RES system [42, 43]. Moreover, some studies found that 
the siRNA lipoplexes could be easily dissociated in the presence of complete serum [44, 
45].  
In our study, all of the cationic liposomes generated by us contain polyethylene glycol 
(PEG), which has been reported to be helpful in avoiding fast clearance and delaying 
uptake of lipid-based nanoparticles into RES. PEG could shield and stabilize the lipid 
bilayer as it is a hydrophilic polymer [46, 47]. However, the addition of negatively 
charged PEG molecules could reduce liposome association with cell membranes, reduce 
cell uptake, and reduce the potential for escape of siRNA from the endosomal 
compartment (essential for antisense activity), thus lowering the overall transfection 
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efficiency [46-48]. To address these issues, we further added a targeting ligand, which 
aided the capacity of liposomes to be taken up into target cells through receptor-mediated 
endocytosis. This led to significant increased in transfection efficiency for the targeting 
liposome compared to our non-targeting liposomes.    
In conclusion, the topical delivery reagent that delivers siTNFα and siMyD88 has the 
potential for development into an effective RNAi therapy for ACD. The targeting 
liposomes, Man-lipo-siIDO and Folate-lipo-siBRAF, could serve as potential anti-
melanoma RNAi therapies. 
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